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ABSTRACT  
 
   
 The goal of this thesis is to test whether Alzheimer‘s disease (AD) is 
associated with distinctive humoral immune changes that can be detected in 
plasma and tracked across time. This is relevant because AD is the principal 
cause of dementia, and yet, no specific diagnostic tests are universally 
employed in clinical practice to predict, diagnose or monitor disease 
progression. In particular, I describe herein a proteomic platform developed 
at the Center for Innovations in Medicine (CIM) consisting of a slide with 
10.000 random-sequence peptides printed on its surface, which is used as 
the solid phase of an immunoassay where antibodies of interest are allowed 
to react and subsequently detected with a labeled secondary antibody. The 
pattern of antibody binding to the microarray is unique for each individual 
animal or person. This thesis will evaluate the versatility of the microarray 
platform and how it can be used to detect and characterize the binding 
patterns of antibodies relevant to the pathophysiology of AD as well as the 
plasma samples of animal models of AD and elderly humans with or without 
dementia. My specific aims were to evaluate the emergence and stability of 
immunosignature in mice with cerebral amyloidosis, and characterize the 
immunosignature of humans with AD. Plasma samples from 
APPswe/PSEN1-dE9 transgenic mice were evaluated longitudinally from 2 
to 15 months of age to compare the evolving immunosignature with non-
transgenic control mice. Immunological variation across different time-points 
  ii 
was assessed, with particular emphasis on time of emergence of a 
characteristic pattern. In addition, plasma samples from AD patients and 
age-matched individuals without dementia were assayed on the peptide 
microarray and binding patterns were compared. It is hoped that these 
experiments will be the basis for a larger study of the diagnostic merits of the 
microarray-based immunoassay in dementia clinics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  iii 
 
 
To Dawn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  iv 
ACKNOWLEDGEMENTS 
 
My studies were funded by grants from the Arizona Alzheimer‘s 
Consortium and the Alzheimer's Drug Discovery Foundation (ADDF). I am 
indebted to Dr Alex Roher, Dr Bao-Xi Qu and Dr Roger N. Rosenberg for 
providing the plasma samples used in most of my experiments, and Kathy 
Goehring and Dr Stephen W. Coons for their assistance with 
immunohistochemistry. I also acknowledge Dr Bart Legutki, Rebecca 
Halperin and John Lainson for their help developing the immunoassay and 
for the production and quality-control of microarray slides. Finally, I am 
indebted to Drs Phillip Stafford and Kewei Chen for their statistical advice.  
 
 
 
 
 
 
 
 
 
 
 
 
  v 
TABLE OF CONTENTS  
          Page 
 
LIST OF TABLES ......................................................................................... vii  
LIST OF FIGURES ...................................................................................... viii  
CHAPTER 
1    INTRODUCTION ....................................................................................  1  
Frequency of Alzheimer‘s disease ................................................. 1 
Symptoms of Alzheimer‘s disease ................................................. 2 
Pathophysiology of Alzheimer‘s disease ........................................ 6 
Challenges in the diagnosis of Alzheimer‘s disease ...................... 8 
Current standard of therapy ......................................................... 13  
Inflammatory changes in Alzheimer‘s disease ............................. 14  
Humoral autoimmunity in Alzheimer‘s disease ............................ 16 
Immunotherapy for cerebral amyloidosis ..................................... 18 
Animal models of Alzheimer‘s disease ........................................ 21 
Proteomics and protein microarrays ............................................ 25 
Types of microarrays .................................................................... 27 
Profiling of humoral responses ..................................................... 30 
Future directions of protein microarrays ...................................... 31 
The CIM random-sequence peptide platform .............................. 31 
2    SIGNATURE OF PURIFIED ANTIBODIES AND MURINE PLASMA .. 33  
Introduction ................................................................................... 33  
 
  vi 
CHAPTER                                                                                               Page 
 
Methods ........................................................................................ 35  
Results ......................................................................................... 37  
Discussion .................................................................................... 59 
3    ANTIBODY SIGNATURE OF ALZHEIMER'S DISEASE ..................... 65  
Introduction ................................................................................... 65  
Methods ........................................................................................ 66 
Results ......................................................................................... 68  
Discussion .................................................................................... 84  
Closing Remarks .......................................................................... 87  
REFERENCES  .......................................................................................... 90 
APPENDICES  
A      EXPLORING PREDOMINANT FORM OF Aβ IN PLASMA............. .104  
B      Testing ANTI-Aβ ANTIBODIES IN HUMAN PLASMA ...................... 107 
  vii 
LIST OF TABLES 
Table Page 
 
1.       Antibody-based therapies for AD in on-going Clinical Trials ............ 21 
2.       Antibodies analyzed with the microarray platform ............................ 38 
3.       Clinical and Neuropathological characteristics of patients. ............... 69 
4.       AD-predicting peptides with alternative statistical techniques..……..83
  viii 
LIST OF FIGURES 
Figure Page 
 
1.       Gradual change in paintings by C. Horn. ............................................ 5 
2.       Appearance of microarray after immunoassay................................. 39 
3.       Heatmap of different anti-Aβ and anti-tau antibodies. ...................... 40 
4.       Signatures of affinity-purified antibodies and plasma ....................... 42 
5.       Histopathological changes in mice. .................................................. 46 
6.       Immunosignature of transgenic mice................................................ 47 
7.       Principal component analysis of plasma signature in mice .............. 48 
8.       Immunosignature changes with Aβ 1-42 immunization. .................. 49 
9.       Principal component analysis of mice signatures. ............................ 50 
10.       Changes in mice immunosignature across time. ............................ 51 
11.       Differences in mice signature according to life stages. .................. 56 
12.       Classification performance of late mice signatures. ....................... 57 
13.       Human immunosignature. .............................................................. 70 
14.       Blocking experiments with Aβ 1-40 beads. .................................... 73 
15.       Fluorescence of array peptides blocked by Aβ 1-40. ..................... 75 
16.       Cross-reactivity of different plasma samples .................................. 76 
17.       Print-run variability……………………………………………………79 
18.       Stability of human immunosignature. ............................................. 81 
19.       Stability of immunosignature in principal component analysis ....... 82 
 
  1 
Chapter 1 
INTRODUCTION 
 
 
Frequency of Alzheimer‘s Disease 
 
Dementia literally means ―losing the mind.‖ It is a term used in 
clinical practice to describe the progressive loss of cognitive ability and 
related behavioral changes. AD is the principal cause of dementia and a 
frequent medical problem. World-wide, it is estimated that 24 million 
people are afflicted with AD [1]. In the United States, about 4.5 million 
people have diagnosis of AD, a figure that is projected to quadruple by the 
middle of the 21st century [2,3]. Although dementia can affect individuals of 
all ages, it is more frequent in the elderly, hence the term ―senile‖ 
dementia. This term, however, has been abandoned; its clinical utility 
derived from the distinction between psychiatric diseases seen in young 
people, or ―dementia praecox‖ (now called schizophrenia), and the organic 
psychosis seen in elderly individuals. AD affects 1/8 of people at age 65 
and almost 1/3 of octogenarians [2,3]. The costs to American health care 
related to AD approach 100 billion dollars every year [4]. Disease 
progression is slow, inexorably advancing over the course of many years. 
It is believed that by the time of symptom onset a significant burden of 
neuropathology and irreversible neurological damage has already 
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occurred: these presymptomatic neuropathological changes are also 
thought to silently evolve over the course of over two decades [5]. Subtle 
cognitive problems are very common in elderly individuals without 
limitation of activities of daily living; in some instances, these symptoms 
may represent the prodromal stages of AD. Such cases of non-disabling 
memory and behavioral complaints without sufficient clinical criteria for the 
diagnosis of AD (referred to as mild cognitive impairment, or MCI) are at 
high risk of developing dementia, converting to frank AD at a rate of 15-
17% per year [3,6-8]. The long prodromal stage of AD presents an 
opportunity to detect individuals who are pre-symptomatic or minimally 
impaired. 
 
 
Symptoms of Alzheimer‘s disease 
 
AD can affect any part of the brain, although the most typical 
involvement is the hypoccampal formation, amygdala, nucleus basalis of 
Meynert, and entorhynal cortex [9]. This localization explains in part the 
initial symptomatology of the disease. The most typical presentation is an 
amnestic syndrome with subtle progression, reflecting ―to a certain 
degree― a predominance of bilateral medial temporal lobe dysfunction 
[8,9]. Many patients and family members confuse these initial symptoms 
with the manifestation of normal aging. However, AD can sometimes have 
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a non-amnestic presentation, which may become a source of clinical 
confusion with other types of dementia. This presentation may feature 
language problems, particularly word-finding difficulties (called ―anomia‖), 
visuo-spatial deficits involving spatial cognition, (i.e., ―agnosia‖; this may 
involve impaired identification of things, places and even faces ―which is 
called ―prosopagnosia‖) and difficulties reading or writing (called ―alexia‖ 
and ―agraphia‖). Finally, AD can present with ―executive dysfunction,‖ 
featuring difficulties making sound decisions (i.e., financially or personally) 
and solving problems. Subsequently, cognitive and behavioral changes, 
―which mainly reflect a more global frontal and temporal lobe 
dysfunction― may ensue, with apathy, change in interest in usual 
activities, poor judgment, derangement of introspection, and speech 
difficulties. Other common symptoms with advanced stages of AD are 
confusion, wandering, perceptual limitation (visual and auditory), 
depression, hallucinations and paranoid delusions, which greatly 
complicate the care and social life of AD patients and their families. 
Hence, AD eventually leads to a broad ―organ failure,‖ with drastic 
intellectual deterioration, personality changes and severe limitation of 
activities of daily living, which render patients largely dependent on care-
takers. During these stages, patients are also prone to accidents, infection 
(pneumonia and urinary tract) and may experience serious neurological 
side-effects from commonly-prescribed medications.  
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The global brain derangement caused by AD is illustrated by the 
case of a famous graphic artist, Carolus Horn [10]. Horn was active, 
preserving until the end of his life the discipline of daily painting. He used 
in his paintings recurrent themes that offer a glimpse into the sequential 
changes of visual perception and constructional praxis that he confronted 
when working on a familiar subject. Figure 1 shows six different depictions 
of a Horn‗s favorite theme, the old bridge in Venice. Strikingly, there is an 
initial change in the choice of colors, transitioning from dark hues to a 
more lively variety of yellows, as well as a progressive abandonment of 
detail and perspective that are hardly attributable to a change of style or 
taste. Horn‘s last drawing displays the same artistic dexterity of a four 
year-old boy. 
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Figure 1: Gradual change in the quality of paintings by C. Horn. 
 
Fig. 1. Progression of Alzheimer‘s disease reflected on C. Horn‘s visual art. 
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Pathophysiology of Alzheimer‘s Disease. 
 
AD is an age-related disorder characterized by the abundant 
deposition of the β-amyloid (Aβ) peptide in the brain parenchyma and 
cerebral vasculature. Aβ is generated from the cleavage of the amyloid 
precursor protein (APP) by the sequential processing of β-secretase 
cleaving enzyme 1 (BACE) and gamma-secretase. Studies of patients 
with trisomy 21 and families with pre-senile dementia suggest that Aβ 
plays a pivotal role in AD pathogenesis [11]. However, genetic mutations 
account for merely 1% of AD cases. The two most important risk factors 
associated with the disease are advanced age and the Є4 allele of 
apolipoprotein E (apo E) [5,8]. Apo E is a lipid transport protein produced 
in the nervous system predominantly by glia; humans possess a 
combination of two of the following alleles: 2, 3 and 4. However, the 
presence of Є4 allele by itself does not lead to AD, given that roughly one-
third of AD patients lack the gene and some homozygotes may not 
develop AD. Put differently, the factors leading to AD are not understood 
in 99% of cases. Thus, the cause of sporadic AD is intricate and multi-
factorial, with contributions from inherited and environmental factors.  
 
 
Aβ deposition in the extracellular space of the brain is considered a 
fundamental feature of AD pathology. However, the production of Aβ is not 
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limited to the central nervous system, and the peptide circulates in plasma 
preferentially bound to several carrier proteins, including albumin, α-2 
microglobulin, apo E, apolipoprotein J, Imunoglobulin G and fibrinogen. 
The predominant laboratory method used for Aβ detection in body fluids is 
an immunoassay, ―double-sandwich‖ ELISA, in which plates are coated 
with anti-Aβ antibodies, then samples are added and finally, another 
antibody directed against Aβ is added; this can be detected with a 
secondary antibody labeled with horseradish peroxydase. This technology 
is not easy to interpret, as the immunological properties of Aβ change as it 
polymerizes. 
 
 
Most studies suggest that Aβ 1-42 levels in the cerebro-spinal fluid 
(CSF) of AD patients detected (using double-sandwich ELISA techniques) 
are lower, on average, than those of control individuals [5]. This is 
attributed to the depletion of the monomeric form of Aβ as its 
polymerization occurs in the brain parenchyma. On the other hand, most 
reports show no differences in plasma Aβ levels between sporadic AD 
cases and non-demented controls, although total plasma Aβ and Aβ 1-42 
levels are increased in cases of familial AD with presenilin or amyloid-
precursor protein gene mutations, as well as in trisomy 21 [11]. However, 
it is presently unclear whether there is a predominant form of Aβ 1-40 and 
Aβ 1-42 that circulates in plasma (i.e., monomer, oligomer or fibrillary). It is 
  8 
argued that the discrepancy across studies of Aβ plasma levels is due to 
the different populations tested, duration of studies, intensity of follow-ups, 
and variability of analytical tools used. In addition, differences in carrier 
protein expression appear to influence Aβ levels in plasma and their 
immunoreactivity, since the interaction between Aβ and transport proteins 
could potentially hide epitopes recognized by antibodies used in double-
sandwich ELISAs [12]. Finally, Aβ oligomers have different immunological 
behavior compared to monomers and fibrils [13].  
 
 
Current challenges in the diagnosis of Alzheimer‘s Disease 
 
No specific tests exist currently for the diagnosis of most types of 
dementia, including AD. The gold standard of AD diagnosis is its 
characteristic neuropathology described more than 100 years ago by Alois 
Alzheimer, which consists of senile plaques, neurofibrillary tangles and 
astrogliosis. This information is rarely available for treating physicians, 
who may corroborate or discard the diagnosis only through autopsy, when 
the information is hardly relevant. In the absence of a histopathology 
report, AD is a diagnosis of exclusion. Contrary to other medical 
conditions that are evaluated with specific tests (i.e., acute ischemic stroke 
is confirmed with diffusion-weighted magnetic resonance imaging, or 
MRI), the typical diagnostic work-up of dementia does not test directly for 
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AD. Instead, physicians test for other neurological diseases that can lead 
to dementia, including stroke, syphilis, hypothyroidism and vitamin B12 
deficiency, leaving AD as a probability. The recent revision of the 1984 
criteria for AD diagnosis by the National Institute on Aging and the 
Alzheimer‘s Association still reflects tremendous diagnostic uncertainty, 
which is patent even at the semantic level [14]. For instance, the 
diagnostic categories include: ―probable,‖ ―possible‖ and ―probable AD 
with evidence of the AD pathophysiological process.‖ This is in spite of the 
important advances in molecular and radiological diagnostics that we have 
discussed. Although AD is a reasonable assumption in suitable clinical 
scenarios, this judgment is prone to error. In fact, the diagnosis of 
―probable‖ AD during life is corroborated in 65-80% of cases submitted to 
autopsy under ideal conditions, i.e., when the diagnosis is made by a 
dementia specialist. In other words, under the best circumstances, 1 out of 
every 5 patients currently receives an incorrect diagnosis of AD.  
 
 
Correct disease classification is imperative for many reasons: 
firstly, some dementias do not respond to the usual symptomatic 
treatment recommended for AD (i.e., cholinesterase inhibitors) or may 
even become worse with it. Secondly, the prognosis of several dementias 
is substantially different from AD; for instance, prion diseases have a rapid 
progression in a few weeks, whereas AD evolves over the course of years 
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or even decades. Lastly, clinical trials involving patients with AD can not 
be considered definitive considering that about 20-25% of enrolled 
subjects may not have the disease. On the other hand, correct prediction 
of AD in persons presenting with vague cognitive complaints (i.e., MCI) 
may present opportunities to slow the progression of neurological decline. 
Therefore, a diagnostic test that helps refine the classification of AD will 
have a very positive impact on patient care.   
 
 
Many therapeutic strategies for AD have emerged recently, holding 
the promise of altering disease course. These include inhibitors of the 
amyloid precursor protein (APP) cleaving enzymes [16] or tau protein 
aggregation [7], as well passive immunization with specific anti-amyloid 
antibodies and pooled human gamma globulin [17], which will be 
discussed in more detail later on. As these approaches to treatment move 
forward to phase 3 clinical trials, the need for reliable tests to diagnose AD 
will only become more relevant. It is equally important that new diagnostic 
options are practical and inexpensive, particularly whenever pre-
symptomatic diagnosis is concerned. In this regard, it is important to 
consider that positron-emission tomography (PET) is not universally 
available, MRI is expensive and has contraindications (such as the 
presence of implanted metal devices), while the measurement of proteins 
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in the cerebrospinal fluid requires a lumbar puncture, which is an invasive 
procedure. 
 
There is a long list of potential biomarkers for AD; however, of 
many surveyed to date, none is used routinely in dementia clinics. 
Historically, AD biomarkers have derived from the amyloid cascade, 
cytokine signaling and neurotubule biology. These tests include: genetic 
testing on selected cases (i.e., Є4 allele), measurement of Aβ 1-42, total 
tau, and hyperphosphorylated tau (181p) in cerebrospinal fluid; 
assessment of cerebral glucose metabolism with FDG-PET; imaging 
cerebral Aβ deposition using PET with Pittsburgh-B compound (PIB, which 
binds to amyloid); estimating hippocampal volume using MRI; and 
standard memory performance tests [7,18]. The present section will briefly 
describe some of them.  
 
 
Currently, PIB is the only amyloid imaging test. It has the drawback 
of a very short half-life (only 20 minutes), requiring that the compound be 
made on site with a cyclotron. This is hardly practical, as this is available 
in only 20 centers nation-wide. A new radiotracer with a longer half-life 
was recently developed by Eli Lily, 18F florbetapir (Amyvid), and may 
become available for clinical use in 2012 [18]. The problems associated 
with PET are the exposure to radioactive tracers, which make the 
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technology unsuitable for frequent follow-up imaging; in addition, the 
anatomical definition of images is far from that obtained with MRI. It is also 
clear that many people with abnormal PET (PIB and FDG) do not have AD 
or may even lack symptoms of dementia, suggesting that PET techniques 
lack specificity for AD. Decreased total apo E plasma levels and low apo 
E4 have been detected in AD patients, particularly in individuals with the 
Є4 allele. These low plasma levels were inversely correlated with cerebral 
load of Aβ estimated by PIB [19].  
 
 
Perhaps the most promising biomarker to date is the CSF signature 
of Aβ 1-42, total tau, and phosphotau (phosphorylated at threonine 181). 
The concentration of these biomarkers is done simultaneously with a 
multiplex immunoassay using the xMAX Luminex platform with 3 specific 
capture monoclonal antibodies. Using CSF from 56 autopsy-confirmed AD 
patients as gold standard, the measurement of Aβ 1-42, levels in CSF 
provided a diagnostic sensitivity of 96.4% on a cohort of 100 AD patients 
and 114 age-matched controls [5]. A very promising aspect of this set of 
biomarkers is that a profile consistent with AD (low Aβ 1-42, high tau) can 
be used to predict conversion of MCI to frank AD with a high degree of 
accuracy.   
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Current Standard of Therapy 
 
Several pharmaceuticals are approved by the FDA for AD 
treatment, although none of these can modify the course of the disease, 
and are mainly used to improve cognitive symptoms and functional scores 
[19,20]. No medications are routinely used to decrease neuroinflammation 
or decrease the bulk of cerebral amyloidosis. The principal drugs currently 
used in dementia patients are the acetyl-cholinesterase inhibitors, which 
increase the concentration of acetylcholine in the postsynaptic cleft in the 
central nervous system. Donepezil, rivastigmine, tacrine and galantamine 
are all acetyl-cholinesterase inhibitors [19,20]. Of these, donepezil is the 
most used agent, in part because is well tolerated and can be used once 
per day. N-methyl-D-aspartate (NMDA) antagonists are also frequently 
used in dementia. This type of drug is exemplified by memantine, which 
reduces glutamate-mediated neuro-toxicity. Many patients with AD require 
other psycho-tropic medications to modify behavior and improve affect. 
Many medications need be used in combination, in order to attain a 
desired effect. A common combination that has been proven beneficial in 
clinical trials is the addition of memantine to donepezil. Unfortunately, 
these medications do not alter neurological progression. Finally, careful 
modification of cardio-vascular risk factors and keeping overall a good 
state of health may also be relevant to slow disease progression. Several 
new drugs are being tested for safety and efficacy. To date, emphasis has 
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been on strategies to manipulate Aβ production, but other mechanisms 
targeted in phase III trials include: inhibition of Aβ aggregation, 
antioxidants, γ-Secretase modulation (including 3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitors, or statins), nerve growth factor mimics, 
and peroxisome-proliferator activated receptor γ (PPARγ) agonists [19]. 
 
 
Inflammatory Changes in Alzheimer‘s Disease     
                                                                              
Although AD is considered primarily a neurodegenerative disease, 
a constant finding in affected individuals is inflammation, which is 
demonstrable in the central nervous system as well as plasma [21-23]. It 
is well known that antigen-presenting cells such as astrocytes and 
microglia are recruited to areas of senile plaque deposition and various 
cytokines are upregulated in brain and plasma of AD cases [23]. The 
immune system‘s participation in AD pathophysiology has different facets 
that can be deemed either favorable or detrimental [21]. For instance, the 
phagocytic clearance of highly insoluble proteins from the extracellular 
space, as well as removal of cellular debris, can be construed as 
beneficial aspects of neuro-inflammation. On the other hand, cytokines 
released by activated microglia and complement activation can promote 
cytotoxicity and accelerate neuronal degeneration [21]. The importance of 
systemic inflammation in AD is such that a characteristic cytokine 
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expression pattern in plasma has been used as a potential diagnostic tool 
for this kind of dementia. Indeed, a study [22] showed that a 120-protein 
double-sandwich ELISA microarray of plasma cytokines can be used to 
classify blinded samples from patients with clinical diagnosis of AD, 
vascular dementia, and non-demented controls with almost 90% accuracy. 
Furthermore, 18 over-expressed cytokines identified MCI cases that 
converted to AD.  
 
 
The premise of a beneficial neuroinflammatory response has 
promoted research aiming at harnessing the immune system for the sake 
of clearing cerebral amyloid deposits [17-19]. The aim of this strategy is to 
modify the natural course of AD. Several studies using transgenic mice 
bearing human mutations leading to AD show that active immunization 
with Aβ can indeed clear plaques from the brain of treated animals [17-
19]. This information seemed compelling enough to justify a human trial in 
which AD patients were vaccinated with synthetic Aβ 1-42. [17]. This trial 
had to be stopped prematurely during its phase 2 because of a 6% 
incidence of T-cell mediated encephalitis in the active treatment arm. 
However, vaccinated individuals who developed measurable anti-Aβ 
immunoreactivity in plasma experienced clinical improvement. The post-
mortem examination of a few vaccinated patients showed inconspicuous 
senile plaques within the brain parenchyma despite otherwise typical 
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findings of AD, including prominent amyloid angiopathy [17]. Alternative 
immunotherapeutic strategies have emerged, including passive 
immunization with amyloid-binding antibodies, which can also clear 
plaques in transgenic mice, as we will discuss later.  
 
 
Evidence of humoral auto-immunity in Alzheimer‘s Disease     
 
Both plasma and cerebrospinal fluid contain naturally-occurring 
anti-Aβ antibodies in normal and pathological conditions [24-26]. However, 
many other antibodies targeting self-antigens are encountered in 
neurodegenerative diseases [27,28]. It is possible that the 
neurodegenerative process of AD offers a growing assortment of epitopes 
to the immune system, which may predate the symptomatic stage. The 
potential exposure of brain antigens to immune surveillance is facilitated 
by the progressive derangement of the blood-brain barrier that 
accompanies AD. Virus-transformed B cells from demented individuals 
have been shown to produce anti-Aβ antibodies [29], while sera from 
normal individuals contain antibodies that bind fibrils of amyloidogenic 
proteins, such as Aβ1-40, serum amyloid A, islet amyloid polypeptide, and 
transthyretin [30]. The latter antibodies do not cross-react with their 
respective monomers and inhibit fibrillogenesis in vitro. This may 
represent a physiological anti-amyloidogenic function (or misfolded protein 
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fail-safe mechanism) of immunoglobulins. In fact, anti-Aβ antibodies 
purified from immunoglobulin preparations can prevent amyloid fibril 
formation and thwart Aβ neurotoxicity [26]. This, however, is in contrast 
with a report showing that serum from APP transgenic mice augmented 
Aβ toxic effects on cultured hyppocampal neurons [31]. Pharmacological 
immunoglobulin preparations (IVIG) used for common neurological 
diseases can bind Aβ in vitro and decrease total Aβ and Aβ1-42 levels in 
the cerebrospinal fluid [24]. Studies using ELISA platforms with synthetic 
Aβ monomers have revealed that AD patients have anti-Aβ antibody titers 
that may be elevated [31,32], low [25], or similar [23] to those detected in 
controls without dementia. Another study using ELISA plates coated with 
oligomeric cross-linked β-amyloid protein species (CAPS) showed that 
anti-CAPS antibodies were reduced in AD patients compared to non-
demented controls, suggesting that these antibodies may alter the 
susceptibility to developing AD [33]. It is unknown why normal individuals 
have anti-Aβ antibodies, although exposure to environmental mimotopes 
of Aβ, such as the potato virus Y has been proposed [34]. On the other 
hand, a recent report revealed that both AD patients and healthy elderly 
individuals possess circulating antibodies that react against tau protein 
(unphosphorylated and hyperphosphorylated) [35]. Some of these 
antibodies were of the IgM class, indicating an acute immune process.  
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As we mentioned, many auto-antibodies commonly detected in 
auto-immune diseases are frequently found both in patients with AD and 
seemingly normal elderly individuals. For instance, the anti-nuclear 
antibodies are found in about 30% of normal elderly individuals at low 
titers (i.e., about 1:80) [27]. Many patients with AD test positive for anti-
nuclear, anti-parietal cell and anti-thyroid microsomal antibodies [27,28]. It 
is presently unclear whether the titer of circulating antibodies against Aβ, 
tau and other relevant antigens changes overtime and whether these 
changes, if any, may correlate with different clinical stages of the disease 
(for instance, the transition from normal cognition to MCI and finally, to 
frank dementia). Results of experiments carried out to evaluate the 
presence of anti-Aβ antibodies in human plasma samples are presented in 
Appendix 2.  
 
 
Immunotherapy for Cerebral Amyloidosis 
 
Immunotherapy for cerebral amyloidosis can be divided into active 
and passive. The earliest report of active immunotherapy in mouse 
models of AD was by Schenk and colleagues [36], who vaccinated a 
group of transgenic mice with aggregated Aβ. The mice used in these 
experiments had a mutation in the APP gene leading to a phenotype that 
featured progressive cerebral amyloidosis. Aβ1−42 vaccination both 
  19 
before and after the expected onset of cerebral amyloidosis resulted in 
extensive clearing of plaque pathology. Other investigations showed 
similar results, with pathological and neurological improvement of treated 
animals [37,38]. 
 
 
These results served as the basis for a phase 1 study in patients 
with AD [39]. The study enrolled 80 elderly individuals who were randomly 
assigned to either aggregated Aβ1−42 (called AN1792) or placebo 
delivered intramuscularly 4 times over 6 months. A phase 2 trial followed, 
which had to be stopped prematurely because of 18 / 298 instances of 
subacute meningoencephalitis (6% of patients), [40] a predominantly T-
cell inflammatory disease that did not correlate with anti-Aβ antibody titers. 
Mirroring effects on vaccinated TG mice, antibodies developed by AD 
patients preferentially targeted Aβ‘s amino-terminus, binding monomers 
and fibrils alike [41]. However, significant antibody titers were detected in 
about 20% of patients, underscoring the technical difficulties of the 
employed detection system (ELISA) and overall lack of suitable biomarker 
availability in AD clinical trials. Although clinicopathological reports [42] of 
vaccinated subjects suggest some clearing or redistribution of senile 
plaques, this did not seem to translate into measurable cognitive 
improvement.  
 
  20 
Passive vaccination is another strategy aimed at counteracting 
cerebral amyloidosis. Injection of monoclonal antibodies produce marked 
neurological improvement in mice, even if plaque pathology or brain Aβ 
levels were not significantly affected [43-45]. This apparent ―dissociation‖ 
between effects on behavior and effects on plaques is not explained 
entirely by neutralization of Aβ in the brain, although it is possible that 
certain forms of Aβ deemed more toxic, such as oligomers, have not been 
always reported, or measured with techniques with debatable merit. Brody 
and Holzman, [46] on the other hand, aptly point out that ―a fundamental 
issue that complicates interpretation of all these results is that we do not 
know whether behavioral abnormalities seen in TG mice are analogous to 
any of the cognitive deficits seen in humans with AD.‖ A potential problem 
with passive immunization is intra-parenchymal brain hemorrhages 
associated with amyloid angiopathy. It is possible that mobilization of Aβ 
out of the brain elicited by therapy may exacerbate amyloid deposition in 
arterioles, a finding that is common in mouse models and almost universal 
in AD patients. Notwithstanding these caveats, a single dose of a 
humanized monoclonal antibody (LY2062430, or solanezumab) as 
potential AD treatment did not result in significant side-effects in 19 
patients [47]. Treatment was not associated with meningo-encephalitis, 
cerebral hemorrhage, or brain edema. Therapy led to dose-dependent 
increases in Aβ levels in both plasma and CSF.  Solanezumab is 
undergoing two separate phase 3 trials: a placebo-controlled trial in Japan 
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(EXPEDITION, ongoing but no longer recruiting patients), and an open-
label trial which is currently enrolling patients [48]. Table 1 summarizes 
current clinical trials of antibody-based therapies for AD. 
 
 
Table 1 
Antibody-based therapies for AD in on-going Clinical Trials 
___________________________________________________________ 
Antibody  Company  Biomarker  Stage 
___________________________________________________________ 
Bapineuzumab Pfizer   11C-PIB  Phase 3 
Solanezumab Eli Lilly/Elan  Plasma Aβ level Phase 3 
Gantenerumab MorphoSys/Roche PIB   Phase 2 
Human IVIG  Baxter   None   Phase 3 
___________________________________________________________ 
 
 
Animal models of Alzheimer‘s disease 
 
Central to the understanding of any human disease is the creation 
of an animal model. Many animal models of AD have been developed to 
date, with variable degrees of success at replicating the histopathology 
and neurological impairment observed in humans. Needless to say, these 
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animal models are considered an approximation to the human problem. 
Careless extrapolation from animal models to the highly complex and 
often times messy circumstances of the average human patient, are 
recipes for confusion and disappointment. Indeed, laboratory animals are 
always raised and treated under controlled circumstances, offering a 
―pure‖ and replicable phenotype, while human‘s phenotypes are the 
product of many synergistic processes, some of which are entirely 
fortuitous or unknown ―in short, patients are impure models. 
 
 
An important step in the development of animal models of AD was 
the application of recombinant technology to the creation of transgenic 
animals with genes from humans with inherited forms of early-onset AD. 
The first used gene was a mutant form of the APP [49,50]. However, these 
early transgenic animals failed to express a meaningful AD-like 
neuropathology. Subsequently, Games and colleagues [51] were able to 
express elevated levels of the V717F mutant form of APP using a platelet-
derived growth factor (PDGF) mini-promoter. These mice, known as 
PDAPP transgenics, recapitulate many pathological features of AD, 
including broad Aβ extracellular accumulation (spreading from the 
hippocampus and increasing with age), astrocytosis and neuritic 
dystrophy. The PDAPP mice exhibit cognitive problems, although its 
correlation with observed neuropathology is unclear.  
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The second set of mutant genes used to create transgenic mice is 
the Presenilin-1 and -2. Deletion of Presenilin-1 in mice proved to be lethal 
immediately after birth, leading to a severe phenotype featuring gross 
skeletal deformities, impaired neurogenesis and intraventricular 
hemorrhage, all in part attributable to the important role of Presenilin-1 in 
embryo‘s Notch processing [52]. On the other hand, Presenilin-2 knockout 
mice are viable, although they develop pulmonary fibrosis [53]. 
 
 
To increase production and, more importantly, cerebral deposition 
of Aβ, some investigators pursued the idea of crossbreeding APP and 
Presenilin-1 mutant mice. Indeed, transgenic animals co-expressing a 
mutant Presenilin-1 gene (called A264E) together with a mutant APP gene 
from a Swedish family (APP Swe) had higher Aβ levels in brain and 
heavier plaque formation than mice carrying only one of the individual 
mutations [54]. A similar phenotype was obtained with mice carrying the 
Presenilin-1 M146L mutation and the APP Tg2576 mutation [55]. Although 
plaque formation begins at 6 months of age in these mice, cognitive 
problems are observed as early as 3 months of age.  
 
 
Finally, transgenic mice have been engineered with 3 mutations 
involving Presenilin-1 (M146I gene), APP (SW) and tau (P301L), 
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controlled by the mThy1.2 promoter [56]. This triple transgenic mice model 
leads to overproduction of tau compared to mice with single tau mutations, 
developing amyloid-laden plaques at 6 months of age and subsequent 
neurofibrillary tangle formation scattered through the hippocampal and 
cortical regions, resembling human AD pathology. Interestingly, ApoE null 
mice do not have plaque deposition or a discernible neurological 
phenotype; these mice, however, develop severe atherosclerosis, 
particularly affecting the aorta [57]. Nevertheless, mutant APP expression 
on apoE knockout mice significantly reduced (but did not abolish) cerebral 
plaque formation [58].  
 
 
Many animal species other than mice have been used for the study 
of AD.  These include non-human primates, the fruit fly Drosophila, the 
sea lamprey, and the nematode Caenorhabditis elegans. Each of these 
animal models possesses a set of advantages, although ultimately, all 
share the same disadvantage: fundamental differences in anatomy, 
physiology and cognition compared to humans with dementia. For further 
details about animal models of neurodegenerative diseases, the reader is 
referred to the two extensive reviews by Götz and colleagues [49,50] As 
we will see in Chapter 1, we used TG mice bearing two mutations from 
patients with familial AD (APPswe/PSEN1-1dE9) to track age-related 
changes in their humoral immune repertoire.   
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Proteomics and Protein Microarrays 
 
Proteins, to use Virginia Espina‘s expression, are ―the verbs of the 
cell‖ [59]. Proteomics, then, is the analysis of cellular grammar: the make-
up of a biological system and the changes that occur not only in response 
to physiological and pathological conditions, but also as result of different 
manipulations (i.e., pharmacological, physical, etc.). It is expected that the 
knowledge derived from such analyses may lead to diagnostic tests, and 
that important insights into specific molecular mechanisms of disease may 
lead to novel therapies. The decoding of the genome of numerous 
species, including humans, has been the stepping stone of proteome 
mining, because the knowledge of species-specific gene sequences 
allows the projection of the amino acid constitution of peptidic chains [59-
61]. Such wealth of information permits the identification of important 
components of cells, tissues, and body fluids. It is also hoped that 
proteomics may help select individuals who are likely to benefit from 
therapies or monitor response to therapy or disease course [60-61]. 
 
 
Traditional proteomic procedures rely on protein separation to 
facilitate analysis. These procedures include SDS-PAGE and two-
dimensional gels, which can subsequently be analyzed with mass 
spectrometry. Needless to say, many limitations have become apparent 
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with these approaches; the main problem being the small amount of 
relevant protein available in a biological sample. It is clear that gene 
transcription and protein expression are not well correlated [60-61]. In 
addition, genomic arrays cannot convey information about post-
translational protein modifications or protein–protein interactions. Many 
times, highly expressed proteins cloud the relative importance of other 
proteins that are present in samples at much smaller concentrations [60-
61]. In addition, conventional analytical methods may be associated with 
considerable cost and time consumption. These limitations provoked the 
emergence of many new proteomic platforms, including protein 
microarrays.  
 
 
Microarrays permit the simultaneous analysis of several molecules 
within the same experiment. Such molecules are spotted in parallel rows 
and columns onto a solid support, and then allowed to react with samples 
containing other binding molecules. The location and intensity of binding 
within each spot requires of sensitive detection systems, which are 
generally based on mass spectrometry, radioactivity, electrochemistry, 
chemiluminescence or fluorescence [62]. Since the location and 
composition of each spot is known beforehand, signals indicative of 
binding can be attributed to the interaction of a specific molecule in the 
array, an identification which can be facilitated by software.  
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Types of microarrays 
 
The first microarrays employed parallel synthesis of nucleotide 
chains on cellulose discs contained in columns or plastic pins. An 
important milestone was the subsequent development of the SPOT 
method, in which peptides are synthesized in parallel on a solid platform 
such as cellulose panes using droplets on a porous membrane‘s surface, 
with an attached reactor for chemical synthesis. This became a popular 
method because the relative simplicity of microarray manufacture and 
detection. Nucleotide arrays enjoyed enthusiastic attention thereafter and 
experienced vigorous development during the eighties and nineties, being 
used for genotyping (of species, individuals, point mutations, single point 
mutations, and short tandem repeats) and gene expression studies. 
However, the development of protein arrays lagged for almost 2 decades, 
in part because of the greater chemical complexity of polypeptide chains, 
and also because of their greater structural frailty.  
 
 
There are two broad approaches to protein microarray production: 
(a) the so-called ―abundance‖-based array, in which capture molecules 
(i.e., antibodies) are spotted on a solid phase; and (b) ―function‖-based 
arrays, in which proteins are generated from cell-free expression systems 
and printed on a slide‘s surface [63]. Several detection systems are 
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employed to detect the binding of relevant molecules to the arrays. For 
instance, the features printed on the array can be labeled directly with 
fluorescent molecules. Alternatively, ―sandwich‖ immunoassays can be 
employed, in which analytes are captured by immobilized antibodies, 
which in turn are detected with a labeled secondary antibody [22]. 
Monoclonal, polyclonal and recombinant antibodies can be printed on a 
slide‘s surface and used to detect proteins from any source. Evidently, 
antibodies will need to adhere preferentially to the microarray‘s solid 
phase by the Fc portion, in order to have the hyper-variable regions 
available for epitope capture. Different antibodies targeting different 
proteins can be printed on pre-arranged spots with pre-set concentrations, 
to allow the correct identification and quantification of binding. This 
technology has been used to characterize the ―signature‖ of neoplastic, 
autoimmune and infectious diseases [63]. 
 
 
In other microarrays, proteins are attached to the slide‘s surface 
through a chemical linkage, i.e., a covalent bond, which is the 
predominant type of microarray used at the CIM. Reverse phase protein 
blot is another production strategy, in which a sample containing many 
molecules is printed on a slide‘s surface and subsequently probed with a 
particular detection reagent. Some techniques entail the design of 
polypeptides featuring fusion tags (i.e., His or GST tags), which 
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respectively adhere to Nickel-coated slides or anti-GST antibodies. The 
protein used on these arrays can be produced using cell-free expression 
systems. Finally, ―self-assembling‖ protein microarrays have been 
developed, in which proteins are produced in-situ [64]. This bypasses the 
tedious protein purification steps usually required for most arrays, and 
more importantly, helps prevent the decay of proteins prior to analysis 
(i.e., during storage or handling), which is almost universally expected in 
most endeavors involving proteomics. Self-assembling arrays are 
produced by printing complementary DNA onto glass slides, which is 
subsequently translated using eukaryotic retyculocyte lysates in situ. 
Newly formed proteins are immobilized in the slides thanks to tags that are 
captured by pre-spotted antibodies on the slides, and subsequently 
detected with another antibody.  
 
 
Different from other methods of microarray development, the 
particle-based peptide array synthesis approach (or ―PepperPrint‖) uses 
chargeable aminoacids directed sequentially on a microchip surface using 
electric field patterns from separate pixel electrodes [65]. This type of 
microarray considerably increases the array density and may be used for 
high-throughput proteomic studies, such as humoral responses against a 
pathogen‘s proteome. 
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Profiling of humoral responses 
 
The traditional approach to antibody detection entails the 
immobilization of a single antigen and subsequent probing with plasma or 
serum, followed by a secondary antibody. This can be accomplished using 
many techniques that are widely used, such as Western blot and enzyme-
linked immunosorbent assay (ELISA). However, there are increasingly 
circumstances in which it becomes desirable to test the presence of 
different antibodies, particularly when it is unclear what is the cause of an 
individual‘s illness. In response to these needs, many antigens can be 
printed on the surface of a slide, providing a multiplex platform for high 
throughput analysis of complex biological samples, such as plasma [61].  
 
Microarrays have been used for epitope mapping of auto-antibodies 
and allergen detection (called ―antibodyome‖ by Andresen and Grötzinger) 
[66]. Protein microarrays have been used for the discovery of novel cancer 
antigens [67]. Some of these platforms detect autoantibodies at the 
presymptomatic stage. For instance, a study using serum samples from 
persons enrolled in the beta-Carotene and Retinol Efficacy Trial (CARET) 
showed that some antigens targeted by autoantibodies in patients with 
lung cancer (annexin I, PGP9.5, 14-3-3 theta and LAMR1) were bound by 
sera from presymptomatic donors [68].  
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Future directions of protein microarrays 
 
Since the human genome is composed by about 25.000 genes, an 
extensive human proteomic microarray should at the very least be able to 
accommodate as many individual proteins as possible on high-density 
arrays. Obviously, this is a daunting task considering the desirable 
dimensions of a practical platform. Some have proposed adopting 
nanotechnology-based solutions, in other words, switching from 
microarrays to nanoarrays. Promising designs include:  planar, attovial-
based and nanowire array designs. Fortunately, there are existing 
technologies for printing nanosized array features, including 
nanodispensing, nanoimprint litography and dip-pen nanolithography. On 
the other hand, there is interest in the development of label-free 
microarray systems, because the use of labels can alter protein-to-protein 
interactions and change protein structure and function. Some of these 
label-free systems include: single plasmon resonance, nanohole array, 
elipsometry, carbon nanotubes and nanowires, and interferometry [63]. 
 
 
The CIM Random-Peptide Microarray Platform 
 
The CIM microarrays consist of maleimide slides with 10,000 
random-sequence 20-mers printed on their surface. Two prototypes, 
  32 
CIM1.0 and CIM2.0 (each with a different set of 10,000 peptides), were 
tested in the experiments that I will describe in detail in subsequent 
chapters. The peptides become covalently-attached to the slides through 
the interaction of the amine-terminus of a Cysteine and the maleimide 
surface. Succinimidyl-4-(N maleimidomethyl) cyclohexane-1-carboxylate 
(SMCC), is used as amine-to-sulfhydryl cross linker. Peptide sequences 
and location in the microarray are known beforehand. The peptides were 
designed using a software that randomly picks 19 natural aminoacids 
(except Cysteine) to build stochastic sequences consisting of 17 residues. 
All peptides have Glycine-Serine-Cysteine linkers at either the carboxyl- 
(CIM1.0) or amino- (CIM2.0) terminus, to space the main aminoacid 
sequence from the slide.  
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Chapter 2 
SIGNATURE OF AFFINITY-PURIFIED ANTIBODIES AND MURINE 
PLASMA 
 
 
Introduction 
 
Why use an antibody assay for the assessment of a 
neurodegenerative disease? In the introduction of this thesis I discussed 
that currently, physicians have no accurate means to establish the 
diagnosis of AD, except when an autopsy is carried out [1-5]. This 
necessarily means that doctors base their diagnosis on the exclusion of 
other neurological disorders, rather than testing directly for AD, which 
misdiagnoses about 20% of patients [1-5]. Although new diagnostic 
techniques are promising, such as the profiling of Aβ and tau in CSF, they 
are not infallible and require a spinal tap, which is not a particularly 
pleasurable experience. On the other hand, amyloid imaging techniques 
such as PIB-PET are not universally available and may be abnormal in 
patients without dementia [6]. Hence, substantial interest exists in the 
development of alternative techniques that may help diagnosing AD. We 
also discussed earlier that the diagnostic merits of auto-antibodies are the 
focus of interest of recent research, because of the simplicity and wide 
availability of the involved analytical techniques and relatively stability of 
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target analytes, antibodies [7-14]. Clearly, immuno-globulins are present in 
senile plaques, and many individuals have circulating auto-antibodies 
targeting different molecules that are relevant in the pathophysiology of 
AD, including Aβ and tau [7-14]. It is also possible that the progressive 
destruction of the cerebral cortex caused by AD unveils novel epitopes to 
the immune system, and more importantly, this might actually predate the 
symptomatic stage of AD by many years [15-21]. The de novo exposure of 
brain antigens to immune surveillance is facilitated by the progressive 
failure of the blood-brain barrier that accompanies neurodegenerative 
processes, including AD [15]. Therefore, a test capable of assessing such 
humoral response may be harnessed as a diagnostic platform.  
 
 
In this section of the doctoral thesis, I will describe an 
immunoassay that can be used to evaluate the signature of antibodies, 
called ―Immunosignature,‖ which employs the random-peptide microarray 
described in the previous chapter. It will be my purpose to describe how 
the immunoassay works and show experiments with affinity-purified 
antibodies as well as plasma from mice.  
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Methods 
 
Description of the microarray-based immunoassay: After the 
production of and storage of microarray slides, they are pre-washed for 5 
minutes with a solution containing 33% isopropanol, 7.5% acetonitrile and 
0.5% trifluroacetic acid in distilled water, then inserted in a TECAN 
HS4800-Pro automated incubator (Männedorf, Switzerland). This machine 
allows the programming of experiments with standardized incubation 
times and washes (TBST followed by water), as well as controlling 
temperatures. The first step of the process is blocking with 0.015% 
mercaptohexanol / 3% BSA / 0.05% Tween 20 in PBS (pH 7.4) for 1 hour 
at 20˚C, to decrease non-specific binding. Subsequently, the primary 
antibody is incubated (typical concentration varies was 10-50 nM or 
plasma at 1:500 dilution in 3% BSA / 0.05% Tween 20 in PBS) for 1 hour 
at 37˚C. Next, biotinylated, species-specific antibodies (targeted against 
rabbit, mouse, goat and human IgG, purchased from Bethyl, Montgomery, 
TX) are incubated on the slides at 5 μM, also for 1 hour at 37˚C, followed 
by Streptavidin conjugated to Alexa 647 or 555 (Invitrogen, Carlsbad, CA; 
concentration was also 5 μM). The TECAN dries out the slides after 
approximately 15 minutes and rings an alarm to indicate that the program 
is complete.  
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Slides are then scanned with a Surescan high-definition laser 
scanner (Agilent Technologies, Santa Clara, CA) to generate digital 
images (TIFF files) which are subsequently processed with GenePix Pro 
6.0 (Axon Instruments, Union City, CA). This is a rather tedious process 
that requires the alignment of frames that convey the exact localization 
and identification of each peptide in the microarray. Saved files can then 
be used for data analysis. 
 
 
Microarray analysis: Scanned data was loaded into GeneSpring 
7.2.1 (Agilent Technologies, Santa Clara, CA) and analyzed. Signals were 
deemed present when intensities were >1 standard deviation from mean 
local background. Peptide identification was done using t-tests, Model I 
(fixed effects) 1-way or multi-way ANOVA, and correlation to specific 
expression patterns.  Clustering techniques, including k-means, 
hierarchical clustering, and Self-organizing Maps were used for identifying 
antibody binding patterns. We screened for technically irreproducible 
values during data pre-processing. Each peptide array replicate provides a 
1.5-fold minimum average detectable fold change at α=0.05 and β=0.20. 
Appropriate false-positive corrections were used.  
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Results 
 
Binding patterns of affinity-purified antibodies against Aβ and tau: 
First, I endeavored to determine whether specific antibodies targeting 
peptides relevant to AD pathophysiology showed distinctive microarray 
binding patterns. I analyzed the signature of 11 monoclonal or affinity-
purified antibodies: 7 against Aβ (4 monoclonal, 3 polyclonal) and 3 
against tau (2 monoclonal, 1 polyclonal, summarized in Table 2). An anti-
human albumin polyclonal antibody raised in goat (A 7544, Sigma) was 
used as control.  
 
 
Each antibody bound different microarray peptides above median 
signal threshold (3-sigma). Binding intensity and order in which reactive 
peptides are ranked yielded specific information regarding each antibody. 
Peptides bound by each antibody were distinct and formed a distinctive 
pattern (Figure 2). The microarray segregated the signature of every 
individual antibody from the secondary biotylinated antibody by itself (anti-
rabbit or anti-mouse) and from other monoclonal and polyclonal antibodies 
(Figure 3). The signature of the secondary antibody can be subtracted 
from the primary to enhance the specificity of patterns.  
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Table 2 
Antibodies analyzed with the microarray platform 
___________________________________________________________ 
Antibody Antigen  Epitope  Type  Company 
___________________________________________________________ 
4G8    Aβ   residues 17-24     M  Millipore  
DE2   Aβ   residues 1-16    M  Millipore 
2B9  Aβ   residues 1-17     M  Santa Cruz 
BAM-10  Aβ   residues 1-12    M  Sigma 
α-tau 421 tau   Asp residue 421     M  Millipore 
α-tau 210 tau   residues 210-241    M  Millipore  
α-Aβ 1-40  Aβ   carboxyl-terminus    P  Calbiochem  
α-Aβ 1-42   Aβ   carboxyl-terminus    P  Sigma 
α-Aβ oligo  Aβ   Aβ octamers     P  Biosource 
α-phos tau   tau  210-threonine 231    P  Millipore 
___________________________________________________________  
Abbreviations: M= monoclonal; P=polyclonal (all raised in rabbit). 
 
 
Figure 2 shows a scanned microarray after completing the assay of 
3 rabbit polyclonal antibodies against Aβ. The white boxes represent 
equivalent areas within the array, which are expanded above for greater 
detail. Spots represent individual peptides organized in the array; white, 
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red and black colors indicate strong, medium and low antibody binding, 
respectively.  
 
Figure 2: Appearance of microarray after immunoassay 
 
 
 
Fig. 2.  Microarray signatures of anti-Aβ antibodies. Scanned image of peptide 
microarray hybridization of 3 rabbit polyclonal antibodies against Aβ. The white 
boxes represent equivalent areas within the array, which are expanded above for 
greater detail. Spots represent individual peptides organized in the array; white, 
red and black colors indicate strong, medium and low antibody binding, 
respectively. 
 
 
Figure 3 (next page) shows a heatmap demonstrating high 
correlation between antibodies targeting the carboxyl-terminus of Aβ, 
amyloid oligomer and phosphotau. This particular heatmap features 93 
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peptides deemed informative by ANOVA. Polyclonal antibodies targeting 
the carboxyl-terminus of Aβ shared binding pattern similarities with an 
antibody that recognizes Aβ oligomers and an antibody raised against 
phosphorylated tau. Other antibodies, mainly monoclonal IgG targeting the 
amino-terminus of Aβ, shared no binding similarities.  
 
 
Figure 3: Heatmap of different anti-Aβ and anti-tau antibodies. 
 
Fig. 3. The heatmap demonstrates high correlation between antibodies targeting 
Aβ‘s carboxyl-terminus and anti-oligomer and anti-phosphotau antibodies. This 
heatmap features 93 peptides deemed informative by ANOVA. Each pattern is 
represented in duplicate. 
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The carboxyl-terminus of Aβ is crucial for its polymerization, while 
additional amino acid residues in this region translate into greater 
aggregation potential, which provides a potential reason for the similarity 
between the Aβ antibody binding patterns. However, the similarity with the 
phosphotau antibody pattern is enigmatic. The phosphotau antibody used 
in this study reacts with a form of tau that is prone to aggregation within 
neurons. Although tau and Aβ do not share sequence similarity, it is 
conceivable that aggregated tau may share a conformational epitope with 
Aβ oligomers. Interestingly, the anti-Aβ oligomer used herein cross-reacts 
with several amyloidogenic proteins, including α-synuclein, islet amyloid 
polypeptide, prion protein, human insulin, lysozyme and polyglutamine, 
suggesting a common conformation-dependent structure, regardless of 
sequence.  
 
In addition, I found differences between the signatures of the 
secondary anti-rabbit antibody, sera from a rabbit immunized with a 
control antigen (NMI), normal non-immunized rabbit sera and purified IgG 
from normal rabbits (Figure 4). Results were reproducible, with good 
agreement between duplicates run by the same individual (r=0.846-0.966) 
and different operators (r=0.95 for first slide, 0.94 for second one). Taken 
together, these experiments show that the microarray platform can detect 
distinctive patterns of antibody reactivity, and that these patterns are 
unique for each antibody, even if antibodies are raised against the same 
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target. Yet, some similarities are clearly noted, particularly if antibodies are 
raised against monomers or polymers.    
 
 
Figure 4: Signatures of affinity-purified antibodies and plasma 
 
 
Fig. 4. Signature of anti-Aβ oligomer polyclonal antibody raised in rabbit. 
Heatmap of a select peptide array signature of anti-Aβ oligomer polyclonal 
antibody raised in rabbit, using hierarchical clustering. The heatmap sets apart 
the antibody signature from the secondary anti-rabbit antibody, sera from a rabbit 
immunized with a control antigen (NMI), normal non-immunized rabbit sera and 
purified IgG from normal rabbits. 
 
 
Immunosignature of APPswe/PSEN1-1dE9 transgenic mice: As we 
discussed in previous sections of this thesis, APPswe/PSEN1-1dE9 TG 
mice are engineered with 2 human mutations found in familial AD, 
affecting the amyloid precursor protein and presenilin-1 genes [22-27]. 
The resulting phenotype is well characterized, consisting of progressive 
amyloidosis involving cerebral cortex, astrocytosis, and neurodegene-
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ration beginning at about 6 months of age, while cognitive impairment is 
noted around 9 months of age [22-27].  
 
 
To investigate whether the immunosignature of TG mice differs 
from littermates, we purchased TG mice from Jackson Laboratories (Bar 
Arbor, ME), as well as non-transgenic controls (B6C3F1/J). In addition, 
plasma from vaccinated TG mice was provided by Dr Roger N. Rosenberg 
(Department of Neurology, University of Texas-Southwestern Medical 
School, Dallas, TX). At Dr Rosenberg‘s laboratory, 5 TG mice were 
vaccinated with a plasmid encoding Aβ 1-42, while 7 were vaccinated with 
mock DNA. All plasmids were delivered through gene gun for 10 doses. 
Two non-TG, non-immunized BALB/c mice were used as additional 
controls. Plasma samples were obtained at the time mice were sacrificed 
(15 months of age).  
 
 
We used TG mice bearing two mutations from patients with familial 
AD (APPswe/PSEN1-1dE9) to track age-related changes in their humoral 
immune repertoire, which I will describe in detail later.  A group of 
B6C3F1/J non-TG mice was used as control. These animals were used 
for regular plasma harvesting at monthly intervals until they were 
sacrificed at 15 months of age. All mice were female, in order to facilitate 
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handling and housing. A total of 5 TG and 5 non-TG mice were purchased 
(from Jackson Laboratories; Bar Arbor, ME) and housed with standard 
chow and water provided ad libitum. All murine experiments were 
conducted under a protocol reviewed and approved by the Arizona State 
University Institutional Animal Care and Use Committee. Mice were 
sacrificed at 15 months of age through intra-peritoneal injection of 
tribromoethanol (5 mg) followed by intra-cardiac ex-sanguination and cold 
PBS perfusion.  
 
 
As we were interested in confirming the development of a 
characteristic neuropathology described in TG mice, brains were carefully 
dissected and removed from the skull after decapitation, rinsed 
sequentially in cold water (to lyse erythrocytes), soaked in cold PBS, and 
finally split across the mid-axial line. Samples were immediately fixed in 
cold PBS-buffered 10% paraformaldehyde for 12 hours and then 
embedded in paraffin for immuno-histochemistry. Every fifth section (with 
a thickness of 5-μm), was stained with hematoxylin and eosin. The 
Ventana automated slide preparation system was used for slide 
processing. In brief, the Ventana system heats slides and treats them with 
xylene, graded ethanols (100%, 95%, 75% and 50%), and distilled water. 
For immunostaining, slides were washed in full-strength formic acid for 2 
minutes for antigen retrieval and dehydrated through graded alcohols. 
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Amyloid staining was attained with NovoCastra NCL anti-Aβ antibodies at 
1:50 dilution. GFAP staining used anti-GFAP polyclonal antibodies from 
Athena Diagnostics, at 1:100 dilution. The secondary antibody was a 
biotin-conjugated rabbit antibody incubated for 30 minutes at room 
temperature, followed by incubation with streptavidin-peroxidase. 
Peroxidase activity was detected with diaminobenzidine 
tetrahydrochloride.   
 
 
Although standardized cognitive tests were not performed, the TG 
mice were clearly different from the control group: the former were much 
more docile and easier to handle. TG mice had heavy cerebral amyloid 
deposition and astrocytosis as compared to B6C3F1/J controls, which was 
apparent on both Hematoxylin-Eosin staining and immunohistochemistry 
(Figure 5). The microarray signature of plasma from 10-month old TG 
mice (n=5) was different from 4 age-matched non-TG littermates 
(B6C3F1/J). Figure 6 shows the heatmap of 113 microarray peptides 
capable of discriminating between plasma signatures of APPswe/PSEN1-
1dE9 transgenic (TG) mice (n=5) and non-TG B6C3F1/J littermates (n=4). 
In the heatmap, blue tones indicate low binding and red, avid binding 
(which occurs when more antibodies bind to the spotted random-peptide), 
whereas yellow designates intermediate binding. Plasma pools 
segregated with their constituting samples.  
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Figure 5: Histopathological changes in mice. 
 
 
Fig. 5. Hematoxylin-Eosin staining shows widespread cortical senile plaque 
formation (arrows) and astrocytosis in TG mice (A) but not in B6C3F1/J controls 
(B). Staining with anti-Aβ antibodies reveals extensive amyloidosis in TG mice 
(C) but not in controls (D). Immunolabeling of glial fibrillary acidic protein (GFAP) 
showed dense astrocytosis. Stained cells were endowed with prominent fibrillary 
processes (red arrowheads). Magnification: 400X (except D, which is 200X). 
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Figure 6: Immunosignature of transgenic mice. 
 
 
Fig. 6.  Immunosignature of transgenic mice. Heatmap of 113 microarray 
peptides that can discriminate between plasma signatures of APPswe/PSEN1-
dE9 transgenic (TG) mice (n=5) and non-transgenic B6C3F1/J littermates (n=4). 
Blue tones indicate low binding and red colors, avid binding (more antibodies 
bound per spot), whereas yellow hues designate intermediate binding. Notice 
that plasma pools segregate with individual samples. 
 
 
A principal component scatter plot also proved useful to discriminate 
between the same mice plasma samples (Figure 7). Furthermore, the 
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microarray detected changes in the signature of TG mice immunized with 
a plasmid coding for human Aβ 1-42. A heatmap encompassing the entire 
10,000 peptide array signature of serum samples from 15 month-old TG 
mice was generated (Figure 8), which sets apart 3 groups: on the far left, 
TG vaccinated with mock DNA; center-right, TG mice vaccinated with a 
plasmid coding for Aβ 1-42; and to the far right, serum samples from non-
transgenic non-vaccinated C57 mice (NTG).  
 
 
Figure 7: Principal component analysis of plasma signature in mice. 
 
 
Fig. 7. PCA plot showing same mice plasma samples as in figure 5. Transgenic 
(TG) mice are represented in yellow and non-TG controls in red. 
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Another principal component scatter plot is shown in Figure 9, 
demonstrating segregation of plasma signature from mock DNA-treated, 
Aβ 1-42 plasmid-treated TG and non-TG mice. Aβ immuno-histochemistry 
revealed heavy amyloid deposition in the brain parenchyma of mock-
vaccinated TG mice, whereas TG mice treated with Aβ plasmid had 
reduced amyloid deposits. Three microarray peptides avidly bound by 
plasma from mice vaccinated with Aβ also were among the top binders of 
the 7 commercial anti-Aβ antibodies that we discussed previously. 
 
Figure 8: Immunosignature changes with Aβ1-42 immunization. 
  
Fig. 8. Heatmap showing signature of plasma samples from 15 month-old TG 
mice. Three groups are noted: on the left, TG vaccinated with mock DNA; center-
right, TG vaccinated with a plasmid coding for Aβ1-42; and to the far right, serum 
samples from non-TG non-vaccinated C57 mice (NTG). 
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These experiments demonstrate that TG mice have a distinctive 
immunosignature that can be altered by genetic immunization, although a 
minimal component of the signature is shared with specific anti-Aβ 
antibodies. However, the animal model used has limitations in that it does 
not fully recapitulate all features of AD; in particular, APPswe/PSEN1-
1dE9 mice do not develop neurofibrillary tangles. 
 
Figure 9: Principal component analysis of mice signatures. 
 
Fig. 9. Segregation of plasma signature from mock DNA-treated, Aβ 1-42 plasmid-
treated TG and non-TG mice. Principal component scatter plot demonstrating 
segregation of plasma signature from mock DNA-treated, Aβ1-42 plasmid-treated TG 
and NTG mice. 
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Stability of murine immunosignature: the immunosignature platform 
offers the opportunity of tracking the immuno-reactivity to different 
peptides overtime. Looking for possible fluctuations of the signature over 
time, I assayed plasma pools from APPswe/PSEN1-dE9 mice and 
B6C3F1/J non-transgenic controls drawn monthly, starting at 2 months of 
age and ending 13 months later (2-15 months).  
 
Figure 10: Changes in immunosignature across time. 
 
Fig. 10. Progressive build-up of signature in TG mice. Heatmap with 39 peptides 
with sustained immune-reactivity overtime in TG mice as compared with 
B6C3F1/J controls. The y axis lists the different peptides, whereas the x axis 
depicts plasma pools from TG mice and age-matched controls. 
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A two-tailed t-test (P=6.6 x10-7 to 6.7 x10-5) was used to find 
peptides that discriminated all TG mice from their non-TG controls, 
yielding a total of 39 peptides (listed in Table 3). Although this was a two-
tailed t-test, these peptides showed higher binding in TG mice. The 
signature was evident even at 2 months of life (Figure 10, above). Notably, 
the immunoreactivity of these peptides became progressively stronger 
with TG mice plasma, remaining low or becoming fainter with B6C3F1/J 
plasma. Plasma samples highly correlated with replicates and other 
samples obtained at different time-points. Using the ―Expression Profile‖ 
feature of Gene-Spring 7.3.1, which allows the detection of immuno-
reactivity patterns that correlate to arbitrary patterns drawn by the 
operator, we noted that most microarray peptides have an intricate 
immuno-reactivity pattern which moderately fluctuates overtime. Such 
complexity is exemplified by the finding that only 2 out of 10.000 peptides 
had a reactivity profile that highly correlated to a traced flat line (Pearson‘s 
correlation coefficient >0.7). The differences in the immunosignature of 
both mice groups changed at different time points, with the immune-
reactivity of many peptides exhibiting high immune-reactivity at 2 months 
of age in TG mice (when cerebral amyloidosis first becomes apparent), 
but declining thereafter. In contrast, an unrelated set of 24 peptides had a 
similar trend in B6C3F1/J controls. The immune-reactivity of 17 additional 
peptides peaked at age 6 months to decline thereafter in TG mice 
(compared to 2 unrelated peptides in B6C3F1/J controls), whereas a 
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different set of peptides (n=77) had a steady reactivity decline in this mice 
group (42 unrelated peptides followed a similar trend in B6C3F1/J 
controls). These observations suggest that the plasma signature of TG 
mice can be distinguished from that of B6C3F1/J controls, and that the 
signature remains largely stable overtime or becomes better defined. 
However, some peptides seem more reactive at different times in life, 
suggesting that many possible epitopes are targeted by the immune 
system as the underlying pathological process evolves. The antibody 
signature of TG emerges early in life: incipient plasma reactivity against a 
set of peptides was detected in TG mice as early as 2 months after birth, 
before significant neuropathological or neurological signs are expected. 
Although these animal experiments cannot rigorously be extrapolated to 
humans, its relevance is that it is possible that an immunosignature, if 
present in humans, may be detectable during the early or even pre-
symptomatic stages of disease, as humoral immune responses generally 
predate the onset of pathological and clinical signs of many diseases. 
 
 
Classification of young mice using late immunosignatures. It is 
generally agreed in the literature that an effective AD therapy is likely to 
depend upon early detection and treatment [15]. In spite of recent 
advances [4-6], no specific tests are universally used to diagnose AD. As 
the pathology slowly progresses for decades before the initial symptoms 
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emerge [16], and since the initial manifestations are generally subtle [17-
21], a potential diagnostic test for AD must be highly sensitive. Given that 
future treatments are likely to target people with mild or no symptoms 
[15,17,18], the test must also be highly specific. Considering the difficulties 
and time involved in obtaining enough samples from subjects with early 
AD stages, we used again the APPswe/PSEN1-dE9 mice, to explore the 
possibility of developing an early stage diagnostic. Specifically, I asked 
whether an immunosignature optimized to detect disease in older animals 
can be used to diagnose the early phases of the disease? This would be 
analogous to using late-stage AD human samples, to train a system to 
detect presymptomatic AD.  To answer this question, mice were divided 
into three groups, according to age: early (2-5 months), mid (6-9 months) 
and late (10-15 months). These time-points are biologically relevant in 
APPswe/PSEN1-dE9 mice, considering that their neurocognitive function 
begins deteriorating at 8 to 9 months of age and their characteristic 
neuropathology (cortical senile plaque formation and astrocytosis) is first 
observed from 6 to 7 months of age [22-27], while no neurocognitive or 
pathological abnormalities are apparent before 4 months of age [22]. 
 
 
Figure 11 shows sequential heat maps separating TG and non-TG 
mice at the early, mid and late time-points. Only 35 peptides were 
selected in a t-test between APPswe/PSEN1-dE9 and B6C3F1/J mice at 
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each of the 3 time-points.  This was done for 3 reasons: first, in all cases 
there were at least 35 peptides that survived multiple-testing correction 
(FWER=5%). Second, it is easier to demonstrate any overlap in peptides 
from one time-point to another when a fixed number of peptides are used. 
Third, the classifier we use (Linear Discriminant Analysis, LDA) works best 
when less than 100 features are used, and 35 features suits this algorithm 
well.  The three 35-peptide sets chosen using a two tailed t-test (early 
P<1.61x10-5, mid P<1.113x10-4, late P<8.73x10-5) readily separated TG 
from non-TG mice at specific time-points, as is shown in Figure 10.  Of 
these optimal peptides, there were only 3 that overlapped between early 
and mid-stages, and 8 that overlapped between mid and late signatures.  
No peptides overlapped between the early and late stages, suggesting 
differences in the ongoing pathological process through the different time-
points. 
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Figure 11: Differences in the signature according to life stages. 
 
Fig. 11. Classification performance of immunosignatures obtained at different 
time-points, first looking at differences between age-matched TG and non-TG 
mice, then applying age-specific signatures to the classification of mice of 
different ages. (a) Heatmap depicting plasma pools obtained from 
APPswe/PSEN1-dE9 mice (TGP) and B6C3F1/J controls (CP) from 2-5 mos of 
life (early samples). Immunoreactivity of the 35 random-sequence peptides (early 
peptides) used here were significantly different between TGP and CP (peptides 
and sequences are listed on the Supplementary table); at the bottom of (a) is a 
PCA display of the same plasma pools using the same 35 peptides, showing 
relative differences between plasma obtained early in life when the early peptide 
set is used. (b) Heatmap (top) and principal component display (bottom) of 
plasma pools obtained at 6 to 9 months of age (mid group), showing another set 
of 35 peptides that can also distinguish between TGP and CP. (c) Same 
experiment using plasma pools obtained late in life (months 10-15 of age). The 
Venn diagrams show the number of peptides that overlap between each set. 
There was no overlap between peptides selected from early and late stages. 
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I evaluated whether the 35 peptides distinguishing TG from non-TG 
littermates late can differentiate the groups early.  As shown in Figure 12, 
late peptides discriminated early disease with a 21% error rate (via LDA, 
Leave One Out Cross-validation).  Mid stage peptides also separated 
groups using plasma obtained at early stages with 18% error, while late 
stage peptides distinguished the source of plasma drawn at mid stages 
with 8% error.  None of the 39 peptides shown in Figure 9 that generally 
discriminate TG from non-TG mice across all time-points appeared in the 
list of 35 optimized for each stage, suggesting that there are antibodies 
specific to each disease stage. When asked to find antibodies present 
throughout the entire disease, the array may have identified lower affinity 
and lower specificity antibodies than the stage-specific ones.  
 
Figure 12: Classification performance of late signatures. 
 
Fig. 12. Accuracy of mouse classification using stage-specific signatures. 
Optimal peptide sets from early, mid and late life stages were used to classify 
plasma obtained at different ages. (a) Late peptides discriminated early samples 
with 21% LDA error rate; (b) Mid peptides classified early samples with 18% LDA 
error rate; and (c) Late peptides classified mid samples with 8% error rate. 
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I also investigated whether the resolving power of late stage 
peptides on early stage samples could be improved by including more 
peptides that were informative against late stage disease. The top 130 
predictive peptides (p<0.000117) for late stage discrimination included 
exactly all 35 early peptides.  When these 130 peptides were used to 
distinguish transgenic mice at early stages, the error rate was zero (even 
so, the visual grouping by heatmap or PCA was noticeably worse than 
using only the 35 early peptides). Since the late stage peptides had some 
positive predictive power for early stage, we asked whether the 35 early 
peptides could predict when mixed with non-informative peptides.  We 
added 95 randomly chosen peptides to the 35 early peptides to make a list 
of 130 peptides; the LDA misclassification rate was 10%, suggesting that 
the 35 early peptides could still perform fairly well even in the presence of 
random noise but also that there was some predictive power for early 
disease in the larger list of late-stage peptides. 
 
Correlation between IgG purified from brain and plasma: finally, we 
asked the question whether IgG present in the brain has a similar 
signature to the one observed in plasma. Small amounts of IgG are 
normally found in the brain, reflecting leaking from plasma as well as local 
production. Additionally, IgG can be detected in senile plaques [28]. As we 
discussed, TG mice had heavy cerebral amyloid deposition and 
astrocytosis (Figure 5). We found a high correlation (r=0.96 to 0.998) 
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between binding patterns of brain-purified and plasma-purified IgG (n=4, 2 
TG and 2 B6C3F1/J). The antibody signature was different for each 
individual, but similarities were again noted between TG and controls. 
There was a high correlation between the signatures of IgG and the whole 
plasma from which it was purified (r=0.99). This similarity between the IgG 
signature of murine brain and plasma suggests that the same assortment 
of antibodies is being detected by the microarray platform. While cross- 
contamination between blood and brain is possible during sample 
processing, it is well known that IgG can cross the blood brain barrier. In 
fact, the blood-brain barrier becomes more permeable to macromolecules 
as individuals age, particularly in the setting of chronic neurodegeneration.      
 
 
Discussion 
 
Evaluating the potential of immunosignaturing as a diagnostic test 
for early AD, I and my mentors at CIM first looked at the stability of the 
signatures in mice. There appears to be a distinctive TG mouse signature, 
which remains stable over time with some variation. The signature has 
both a general group aspect and one that is individual, such that the 
samples from the same mouse over time were very similar. Employing the 
APPswe/PSEN1-dE9 mouse model and age-matched controls, blood was 
collected from individual mice from months 2 to 15 of life.  When 
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considering only TG and non-TG groups without incorporating the time of 
collection, it was found that as few as 39 peptides could separate the two 
groups of mice, with a signature that increased over time (in Figure 9 there 
are ~8 peptides that seem to show a distinct increase in signal over time in 
the heatmap).  The mice were then divided by age into early, mid and late 
stages.  We selected 35 highly significant peptides using a standard t-test 
between TG and non-TG mice at each stage.  There was little overlap 
between the sets of peptides characterizing each stage, and none at all 
between late and early stages.  The late stage peptides separated TG and 
non-TG mice at early stages, but with a rather high error rate of 21%, 
while mid-stage peptides performed better (18% error).  Increasing the p-
value cutoff to 0.0001 for late peptides allowed 130 peptides to be 
selected. This set of 130 peptides included the 35 highly selective early 
peptides, and actually did classify the early peptides with 0% error. If 
translated to a clinical setting, one would not know which peptides would 
be best for early diagnostic, but since the early specific peptides were a 
subset of a large set of late peptides, and given that highly specific early 
peptides can still discriminate the disease state even when mixed with 95 
randomly non-informative peptides, provides hope that a diagnostic for 
early diagnosis can be done using conventional patient selection (i.e., 
confirmed diagnosis at late AD stages).  
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The patterns formed with antibody binding to microarrays may have 
a diagnostic potential.  However, the stability of signatures is important for 
two reasons:  first, if the variation caused by time is small, then larger 
sample pools could be used without concerns about noise dampening the 
signature out over time. Second, if there is a personal component of the 
signature, it could be useful for monitoring disease progression or 
response to treatment. TG signatures were highly distinguishable from 
age-matched controls regardless of age. Relative to the second issue, 
there was clearly an individual component observed in mice. 
Mathematically, the two samples from the same individual were most 
similar to each other.  
 
 
Ideally, AD should be detected at the pre-symptomatic or early 
symptomatic stages, when promising disease-modifying therapies are 
expected to exert greatest benefits [15].  Unfortunately, these stages are 
also the least understood aspects of the disease, and the most 
susceptible to diagnostic misclassification with current standards [16-22].  
For these reasons, we are interested in knowing whether the late stage 
signatures can be used to guide an early stage diagnostic.  We used the 
APPswe/PSEN1-dE9 mouse model to address this issue.  While there are 
certainly concerns for the relevance of any mouse model to human 
disease [27], our perspective relative to technology development is that if 
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one cannot demonstrate the feasibility of an approach in a well-controlled 
model system, it is less likely to work in the complexity of humans. 
 
 
The first issue is whether the TG mice are distinguishable by 
immunosignaturing at an early stage of disease.  When the 
immunosignatures of all the TG mice were compared to the non-TG 
littermates, 39 peptides clearly separated the two groups regardless of 
age.  Even mice at two months (when characteristic neuro-pathology is 
not expected), had a distinguishable signature, although noticeably 
weaker than in old mice.  This signature became more intense over time, 
implying that there is more antigen driving the antibody response.  
Interestingly, 7 of the 39 peptides could also react with purified antibodies 
against Aβ, the concentration of which progressively increases with age in 
the brain and plasma of APPswe/PSEN1-dE9 TG mice.  These changes in 
the antibody repertoire of TG mice illustrate the complexity of their 
pathological process, with amyloid overproduction setting off a cascade of 
events where additional epitopes become targeted by the immune system 
as animals grow older. 
 
 
From the practical point of view of developing a human diagnostic 
signature, it will be challenging in the short term to acquire samples from 
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all stages of human AD.  Using the mouse model does not circumvent this 
issue, but helped us to gain relevant insights.  For instance, dividing the 
mice into early, mid and late stage groups, we found peptides from each 
life stage that separated transgenic from non-transgenic mice with 100% 
accuracy.  Of note, there was no overlap between the 35 peptides in the 
late and early stages, and the late stage peptides classified the early 
stage mice with 21% error.  However, based on the mouse data, there 
may be two solutions to this problem.  We found that the informative 35 
peptides for early stage were included in the top 130 late stage predictive 
peptides (p<0.000117).  These 130 peptides had a 0% error rate in 
classifying early stage mice.  Of course, this test is artificial in that we 
knew where to draw the cut-off in order to include the 35 early stage 
peptides.  But it does indicate that an inclusive rather than exclusive 
strategy for choosing late stage peptides for a diagnostic would more likely 
succeed. 
 
 
A second strategy may be based on using samples from people 
with mild cognitive impairment who progressed to autopsy-confirmed AD.  
While there was no overlap between early and late stage peptides in mice, 
there was a 23% overlap between late and mid stage peptides and 9% 
overlap between mid and early.  Therefore, it may be useful to employ the 
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mild cognitive impairment samples to define the early stage peptides for 
the diagnostic. Of course these two strategies are not mutually exclusive. 
 
 
What are the implications of this analysis for developing a 
diagnostic test for early stage AD?  To the extent that the mouse model 
and its associated caveats can guide this effort, it is encouraging in 
implying that a signature of disease starts very early in life.  However, this 
work also implies that optimizing the diagnostic test using late or 
minimally-symptomatic patients may not provide much overlap with the 
optimal early stage signature.  Although the optimal 35 peptides selected 
in old mice were different from the 39 peptides that were useful at all the 
time-points and the 35 optimal early-stage peptides, the last 2 sets of 
peptides became again part of the signature when the p-value cutoff of the 
late-stage comparison was relaxed.  The implication is that late stage 
immunosignatures should be used rather broadly when searching for an 
early AD diagnostic.  This has the shortcoming of introducing non-
informative peptides and subsequent noise in the analysis, but our 
analysis on the mouse samples indicates this may not be prohibitive in 
developing an accurate diagnostic test. 
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Chapter 3 
ANTIBODY SIGNATURE OF PATIENTS WITH ALZHEIMER'S DISEASE 
 
 
Introduction 
 
The major theme of this doctoral thesis is that post-mortem 
examination remains the gold standard of AD diagnosis, an option that is 
rarely feasible or desirable. This has important implications for medical 
practice and clinical trial design: to begin with, the prognosis of dementia 
varies according to the underlying etiology; secondly, pharmaceuticals 
used routinely for AD can exacerbate the symptoms of other types of 
dementia (for instance, donepezil can exacerbate the motor impairment of 
Progressive Supranuclear Palsy, or PSP) [1]; and lastly, clinical trials may 
be distorted if a substantial proportion of enrolled subjects are expected to 
have a wrong diagnosis. A pharmaceutical company conducting two 
phase 3 clinical trials for AD is using a blend of biomarkers to document 
disease progression, including neuro-imaging and Aβ measurements in 
plasma and cerebro-spinal fluid [2-3]. This underscores the necessity to 
develop alternative techniques to diagnose AD and monitor its course.  
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In the previous chapter, I described the application of our 
microarray platform to the study of the binding patterns of affinity-purified 
antibodies and plasma samples from transgenic mice with cerebral 
amyloidosis. In this chapter, I will describe my efforts to develop a 
diagnostic tool for AD based on immunosignatures. Some of these 
experiments have been peer-reviewed and published [4]. 
 
 
Methods 
 
Patient‘s Characteristics and plasma sample handling. Plasma from 
12 patients with probable AD and 12 age-matched controls without 
cognitive derangement were provided by Alex Roher (Banner‘s Sun 
Health Research Institute, Phoenix, AZ). These patients were enrolled into 
a brain-bank program. Postmortem examination was performed by a 
neuropathologist on 9 patients (5 with and 4 without dementia).  Samples 
were acquired after written consent and approval of the Banner 
Institutional Review Board (IRB). Profiling studies were approved by 
ASU‘s IRB (protocol # 0912004625). In addition to these patients, we 
obtained 100 plasma samples from the Alzheimer‘s Disease 
Neuroimaging Initiative (ADNI). ADNI is a comprehensive multi-
institutional project funded in part by the NIH (P.I.: Dr Neil Buckholtz), 
aiming to identify neuroimaging and biomarkers of the cognitive changes 
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associated with MCI and AD [5]. Data acquired through ADNI are made 
available to the general scientific community and the entire repository of 
clinical and imaging data collected is accessible to authorized 
investigators after on-line application, which we submitted on 4-23-2009 
and approved on 7-2-2009. 
 
 
Microarray Platform and Immunoassay: the reader is referred to the 
description on Chapter 1. Regarding Microarray analysis, scanned data 
was loaded into GeneSpring 7.2.1 (Agilent Technologies, Santa Clara, 
CA) and analyzed. Signals were deemed present when intensities were >1 
standard deviation from mean local background. Peptide identification was 
done using t-tests, Model I (fixed effects) 1-way or multi-way ANOVA, and 
correlation to specific expression patterns.  Clustering techniques, 
including k-means, hierarchical clustering, and Self-organizing Maps were 
used for identifying antibody binding patterns. We screened for technically 
irreproducible values during data pre-processing. Each peptide array 
replicate provides a 1.5-fold minimum average detectable fold change at 
α=0.05 and β=0.20. Appropriate false-positive corrections were used. 
 
 
Blocking experiments with Aβ-coated beads: synthetic Aβ 1-40 
covalently attached to TantaGel S NH2 polystyrene beads (Advanced 
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ChemTech, Louisville, KY) were used, carrying approximately 0.2 mmol 
antigen/gram. To decrease non-specific binding, various bead 
concentrations ranging from 1-0.01 mM were pre-blocked with 5%BSA-
PBS. Beads were stored at 4°C overnight and rinsed with 3%BSA-PBS-
0.05%Tween20 prior to mixture with plasma pools dissolved 1:500 in 
3%BSA-PBS-0.05%Tween20. This mixture was incubated at 37°C, 
centrifuged, and the supernatant was assayed on microarray slides as 
previously described.  Blank beads similarly treated were used as 
controls. 
 
 
Results 
 
On average, patients with dementia were older than the cognitively-
normal control (84.5±5.5 years old versus 72.6±7.8, respectively). This 
difference had a trend toward statistical significance (p=0.08) using a t-
test. Most patients were women (7/12 in the AD group and 8/12 in the 
control group, Table 3).   
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Table 3 
Clinical and Neuropathological characteristics of patients. 
___________________________________________________________ 
 
P# Age Sex Pathology Summary PT CERAD Braak 
43 88 F Argyrophilic grains in mesial temporal 
lobe; Lewi bodies; white matter 
rarefaction. Dx: PSP 
14 Prob AD III 
44 81 F -    
48 87 M -    
53 83 F Many plaques and tangles; white matter 
rarefaction 
15 Def AD V 
57 85 F Many plaques and tangles; Lewi bodies 11.2 Def AD V 
59 81 F -    
4 77 F -    
8 80 M -    
11 73 F -    
15 89 M Many plaques and tangles; severe white 
matter rarefaction; 3 small old infarcts 
and 6 old microinfarcts 
13 Prob AD V 
24 90 M Many plaques and tangles, white matter 
rarefaction 
11 Prob AD IV 
26 76 M -    
39 86 M -    
40 83 F -    
41 77 F -    
45 81 F Some senile plaques and occasional 
tangles 
10 Pos AD II 
49 70 F -    
50 73 M Some plaques and tangles, insufficient 
for AD Dx; mild amyloid angiopathy; white 
matter rarefaction; 1 small old infarct; 
many old microinfarcts 
6.5 Not AD III 
1 82 F Not available    
13 60 F -    
16 79 F -    
29 79 F -    
52 90 M Occasional plaques and tangles 4 Not AD III 
56 76 M -    
 
P# is patient ID number; PT= total senile plaque count; CERAD= 
pathology diagnosis (Consortium to Establish a Registry for Alzheimer's 
Disease); Prob= ―probable‖; Pos= ―possible‖; Def= ―definite‖; Braak are the 
Braak scores.  
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Figure 13: Human immunosignature. 
 
 
Fig. 13. (a) Heatmap of 169 peptides that distinguished AD plasma from age-matched 
controls. Patients cluster into 3 patterns: AD-type, intermediate, and non-demented. 
Asterisks denote individuals who had autopsy. (b) Principal component scatter plot 
analysis of same plasma samples, demonstrating that individual plasma samples from 
AD patients (red dots) cluster together, whereas samples from non-demented controls 
(yellow) are widely scattered. (c) Plasma pools (arrow heads) from AD patients and 
cognitively normal controls are also correctly discriminated by the platform. The signature 
of a patient with PSP on autopsy, migrated with the pattern of normal controls. 
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The immunosignatures of these patients formed three different 
patterns: one distinctive of AD, another representative of the non-
demented controls and an intermediate pattern. The former pattern was 
noted on 9 individuals, all with AD (except 1 normal control and the PSP 
patient). The second pattern was seen in 4 cases, (3 controls, 1 AD). The 
intermediate pattern was seen in 4 cases (3 non-demented, 1 with AD). 
The asterisks in Figure 13 denote individuals who had autopsy, which 
confirmed AD in patients # 1, 3, 4, and 7; patient # 8 was diagnosed with 
PSP by the pathologist, whereas patients # 15 and 16 did not have 
significant AD pathology. Panel b shows a principal component scatter 
plot analysis, demonstrating that individual plasma samples from AD 
patients (black dots) cluster together, whereas samples from controls 
(grey) are widely scattered. The numbers near the dots represent patients 
from panel A. Next, we assayed plasma pools from 5 patient groups: 
autopsy-proven AD (n=4), clinical AD without autopsy (n=7), the PSP 
patient, cognitively normal elderly controls without definitive signs of AD 
on autopsy (n=4) and cognitively normal elderly controls without autopsy 
(n=8). The principal component plot shown in panel c of Figure 13 also 
demonstrates that the microarray platform can discriminate between 
different pools, and also that AD patients with or without autopsy cluster 
away from normal controls.  
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Using ClustalW 2.0, an automatic program for global multiple 
alignment of aminoacid sequences [6], we found that none of the 50 
higher ranking peptides bound by the autopsy-proven AD plasma pool had 
sequence similarity with Aβ1-40 or Aβ 1-42. Eleven microarray peptides 
highly bound by the AD autopsy plasma pool were also top binders of the 
7 commercial anti-Aβ antibodies.  
 
The predictive capacity of the immunosignature was assessed by 
re-testing 8 random samples (5 with AD and 3 controls) in a blinded 
fashion. Using the support vector machine algorithm of GeneSpring GX, 
we established a learning data set using known binding patterns exhibited 
by the complete sample set of human IgG.  With this training set, blinded 
samples were assigned to any pattern, which correctly recognized 4 AD 
and 2 control cases but misclassified 2 samples (1 erroneously assigned 
to AD). While these are early results, the data supports the concept that 
different antibody binding patterns are detectable and reproducible, and 
that the immunosignaturing technique could be developed to assist in the 
classification of patients with dementia.   
 
 
Blocking experiments with Aβ-coated beads: to determine whether 
the immunosignatures observed in humans are partly due to Aβ 
immunoreactivity, I carried blocking experiments using synthetic Aβ1-40 
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covalently attached to polystyrene beads to pre-treat plasma pools before 
being assayed. Untreated plasma pools and pools treated with blank 
beads were used as controls. The overall signature of plasma pools did 
not change after blocking with the Aβ-coated beads. However, pre-
treatment with Aβ beads decreased the reactivity of 4 microarray peptides 
as the concentration of Aβ 1-40 beads increased (Figure 14, panel a).  
 
Figure 14: Blocking experiments with Aβ1-40 beads. 
 
Fig. 14. Blocking of plasma immunoreactivity with Aβ-coated beads. Plasma 
pools from AD patients were treated with different concentrations of Tantagel 
beads. (a) Fluorescence declined for a few array peptides as the concentration of 
Aβ 1-40 beads increased. (b) Effects of Aβ 1-40 bead treatment on fluorescence 
intensity of the specific peptides shown above. 
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There was minimal variation with blank beads, whereas minimal 
decline in fluorescence intensity was noted for a plasma pool from normal 
cognitive controls. Panel b depicts a microarray scan showing the effects 
of Aβ 1-40 bead treatment on fluorescence intensity of the specific peptides 
shown above. The immunoreactivity of 2 of these peptides exhibited 
marked decline after Aβ 1-40 treatment. Using ClustalW 2.0, I found no 
sequence similarity between these peptides and human Aβ. Figure 3 is a 
bar graph depicting the fluorescence intensity of the representative array 
peptides blocked by Aβ 1-40 when probed with specific commercial 
antibodies. Some of these peptides strongly bound polyclonal anti-Aβ 1-42, 
anti-Aβ oligomer and anti-phosphotau antibodies. 
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Figure 15: Fluorescence of representative peptides blocked by Aβ 1-40. 
 
 
 
 
Fig. 15. Bar graph depicting the fluorescence intensity of the representative array 
peptides that were blocked by Aβ 1-40 when probed with specific commercial 
antibodies. Notice that only the anti-Aβ 1-42, anti-Aβ oligomer and anti-
phosphotau bound well to some of these peptides. 
 
 
These experiments suggest that only a small portion of the 
signature is driven by anti-Aβ antibodies, and that blocked microarray 
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peptides may behave as epitope mimetics, given the lack of sequence 
homology with the blocking antigen. However, it is possible that an anti-Aβ 
antibody that conveyed a small portion of the signature or one whose 
removal was masked by binding of another antibody would not be 
detected.  
 
Cross reactivity between AD, TG mice and anti-Aβ oligomer antibodies: 33 
peptides were preferentially bound by anti-oligomer antibodies and AD 
plasma, whereas 19 peptides were specifically bound by plasma extracted 
from AD patients and TG mice (Figure 16).  
 
Figure 16: Venn Diagram peptide overlap. 
 
 
 
Fig. 16. Venn diagram representing cross reactivity between different sera. (a) 
highest-ranking peptides bound by plasma from APPswe/PSEN1-dE9 mice, AD 
patients, and the anti-Aβ oligomer antibody. (b) plasma pools from autopsy-
proven AD, normal controls and plasma from a patient with PSP on autopsy. 
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Two random-sequence peptides were avidly bound by all groups: 
KKNFKTFGFDPLVTWSWGSC and GLPWTLYYLWMRPTYVRGSC. The 
probability of this occurring by chance is 8.894 x 10-6. Panel (a) of Figure 16 
shows the number of highest-ranking peptides from the microarray bound by 
sera from APPswe/PSEN1-dE9 transgenic mice, AD patients‘ plasma, and 
the anti-Aβ oligomer antibody. Panel (b) of the same Figure shows a similar 
exercise using pools of plasma from autopsy-proven AD, cognitively normal 
controls without AD features on autopsy and plasma from a patient with 
neuropathological signs of PSP. Inquiry with ClustalW 2.0 found no sequence 
homology between these 2 peptides and human Aβ. Several peptides bound 
predominantly plasma from the PSP patient (29 peptides), the autopsy-
confirmed AD plasma pool (22 peptides), and the plasma pool from elderly 
controls without signs of AD on autopsy (34 peptides). The probability of this 
occurring by chance is 1.25 x 10-7. 
 
 
Influence of print run variability: it was a significant problem during 
my experiments. This is partly explained by the fact that the microarray 
platform was modified while I was standardizing the immunoassay (i.e., 
my initial experiments were done with a microarray with 4.000 random-
sequence peptides). Most of my experiments involved microarrays with a 
solid phase consisting of 2 different sets of 10,000 random-sequence 20-
mers covalently attached to a glass slide‘s surface. The peptides on each 
  78 
microarray were different, designed with Glycine-Serine-Cysteine linkers 
at either the carboxyl (CIM1.0) or amino (CIM2.0) terminus for slide 
adherence. Also, peptide synthesis and printing on the microarray was 
different for both microarrays: CIM1.0 peptides were synthesized by Alta 
Biosciences (Birmingham, UK) and spotted in duplicate using a NanoPrint 
LM60 microarray printer (ArrayIt, Sunnyvale, CA), while CIM2.0 peptides 
were synthesized by Sigma (St. Louis, MO) and printed by AMI (Tempe, 
AZ) using a piezo printer. In addition, problems were detected as the 
microarray was developed, including issues with peptide mixture, pH, 
concentration, printing, and handling. As a result, the reproducibility of 
results depended heavily on the print run. For instance, plasma sample 
replicates had a high correlation (i.e., >0.8) if the same print run was used, 
but less correlation (i.e., 0.4 or less) if different print runs were employed. 
Furthermore, when many print runs are compared, the described AD 
immunosignature became less defined or effaced altogether.  
 
 
Similarly, if the training set of peptides that distinguished AD from 
controls with the Banner-Sun Health samples does not work if samples 
from the same or a different cohort (ADNI) are assayed on slides from 
different print runs. Figure 17 (below) demonstrates this variability when 
ADNI samples are run on slides printed at different times at our laboratory. 
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From these experiments, I learned that experiments required the same 
print run in order to avoid problems with reproducibility.  
 
Figure 17: Print-run variability. 
 
 
Fig. 17. Variability of results because of utilization of multiple print runs. 
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Stability of human immunosignature: as I described in the previous 
chapter, the immunosignature platform offers the opportunity of tracking 
the immuno-reactivity of plasma against different microarray peptides 
overtime. Finding whether a signature is stable overtime in humans is 
relevant for two practical reasons: firstly, if the overall immuno-signature is 
unstable, then the technique may not be suitable for future application as 
a diagnostic test; conversely, if the signature is stable, then it becomes 
pertinent to know at which point exactly it diverges from normal signature. 
In order to explore whether an antibody signature in humans remains 
constant overtime or disappears on follow-up, we assayed 2 plasma 
samples obtained several months apart from 5 patients with AD (including 
the 4 autopsy-proven cases), 6 normal elderly controls (including the 4 
cases with autopsy) and the patient with diagnosis of PSP on post-mortem 
examination. Figure 18 shows that, using a single print-run, plasma 
samples taken at time zero strikingly align with their own follow-up 
samples. Moreover, 53 microarray peptides are capable of discriminating 
between AD and control plasma, whereas the PSP patient exhibits an 
intermediate pattern. On a Principal Component Analysis (Figure 19), AD 
plasma samples appear to aggregate away from controls, no matter if 
samples were taken at time zero or thereafter. Conversely, no discernible 
pattern was noted when time points (time zero versus follow-up) were 
used as the clustering paradigm. Similar results were noted when the 
  81 
same print run of a second microarray platform with 10.000 different 
random-sequence peptides was used.  
 
Figure 18: Stability of human immunosignature. 
 
 
Fig. 18. Heatmap showing short-term stability of AD signature. Heatmap of 
plasma samples from AD and controls taken at time zero and follow-up (usually 6 
mos). 
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Interestingly, one of these 53 peptides cross-reacts with an 
antibody that binds Aβ oligomers, while 7 peptides cross-react with 
plasma from TG mice vaccinated with a plasmid coding for Aβ 1-42. These 
observations suggest that AD plasma has a signature that can be 
distinguished from that of cognitively normal controls, and that the 
signature remains largely stable overtime.  
 
Figure 19: Principal Component Analysis. 
 
 
Fig. 19. Principal component analysis of plasma samples and their follow-up. 
Same plasma samples from Figure 6 are separated topographically in this 
representation. The AD is depicted in red, age-matched non-demented controls 
in yellow and the PSP patient in blue. 
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Alternative methods of data-mining: several microarray peptides are 
preferably bound by AD plasma, even if slides from different print runs 
were used. Table 4 (below) shows a ranking of the top-10 peptides from a 
total of 25 that were useful to distinguish AD plasma from elderly controls, 
regardless of print-run. 
 
Table 4 
 Top peptides predicting AD using other statistical techniques 
Rank ES PEPTIDE SEQUENCE p Value 
1 1.2731 KIAMFKWLMGDNFNWKKGSC 
 
7.2e-006 
 
2 1.2361 RRSVQQYNFYLSQMNQYGSC 
 
1.2e-005 
 
3 1.2018 HKEAWREPWEGKYPFMTGSC 
 
1.9e-005 
 
4 1.1841 HFGAWRFFGTAWYARNPGSC 
 
2.5e-005 
 
5 1.174 ITEETMVQYEYVRIKQDGSC 
 
2.8e-005 
 
6 1.1729 MWKFQPRSNDNPARWNDGSC 
 
2.9e-005 
 
7 1.172 GFHGPGMLGKTGRLSYGGSC 
 
2.9e-005 
 
8 1.1665 KIGKNIHHQQRTMTYTWGSC 
 
3.1e-005 
 
9 1.1597 ISYLKTALALYFIVQESGSC 
 
3.4e-005 
 
10 1.157 KDRFLQKGKQMFVPPWKGSC 
 
3.6e-005 
 
___________________________________________________________ 
Where ES equals effect size (intensity threshold of ≥1.1).  
 
  84 
Using a multiple variable Receiver Operating Characteristic (ROC) 
technique, 25 peptides (Table 2) provided efficient means to predict AD, 
regardless of the print-run used, when the effect size (ES) threshold was 
≥1.1. The combined partial least square (PLS) showed a highly significant 
difference between AD and controls (p=0.000002). Using all of the top-10 
selected peptides with Jackknife technique, an overall sensitivity and 
specificity of 83% was found. Using the highest ranking peptide by itself, 
sensitivity and specificity were 80%. When the 3 most significant peptides 
were used, 87% sensitivity 87% and 77% specificity was attained. Using 
the top 5 most significant peptides, the sensitivity was 90% and specificity 
77%. Using the 8 most significant peptides, the sensitivity and specificity 
were 87%.  
 
 
Discussion 
 
I have described herein a novel method to assess the 
immunoreactivity patterns of humans with or without AD. The used 
microarray platform features 10,000 random-sequence peptides that 
appear to behave as mimetics of the original targets of tested antibodies. I 
demonstrated that plasma of elderly patients with or without dementia 
reacts with microarray peptides, and that this reaction takes the form of 
different patterns that allowed us to discriminate, to certain degree, 
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between patients with or without disease. Furthermore, I showed that the 
bulk of the immunosignature is independent of Aβ. 
 
 
I also identified a set of random peptides from the array with the 
highest binding by particular plasma samples, allowing plans for 
development of arrays with reduced number of peptides, or individual 
ELISAs using random peptides as antigen. This high-throughput screening 
platform has been used for identifying surface-immobilized peptides which 
specifically bind bacterial lipopolysaccharides [7-8], guiding production of 
synthetic antibodies [9] and characterizing humoral response to infections 
and vaccination [10], but not until now employed until now to evaluate a 
chronic disease such as dementia.  
 
 
In a different proteomic approach to the assessment of dementia, a 
double-sandwich ELISA microarray featuring plasma cytokines was used 
to classify blinded samples from patients with clinical diagnosis of AD with 
almost 90% accuracy [11]. Compared to such platform, our microarray has 
3 advantages: (a) it multiplies by 83.3 the number of analytes, (b) it assays 
antibodies, as opposed to cytokines, which are very stable, and (c) it is 
inexpensive, with average slide cost of about $50.  
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As previously said, AD diagnosis is an imprecise process of 
exclusion of other neurological entities, as illustrated by the misdiagnosis 
of the PSP patient. The gold standard of AD diagnosis is its characteristic 
neuropathology, which is rarely available to clinicians. Correct disease 
classification is imperative for obvious reasons; therefore, a simple test 
that helps refine the classification of dementia is needed. Also, many auto-
antibodies, including anti-Aβ and anti-tau are found in normal elderly 
individuals at low titers. However, it is unclear whether titers change 
overtime or correlate with different clinical stages. I speculate that 
autoantibodies react to the microarray peptides, accounting in part for the 
observed signatures. This assertion is based on our finding of microarray 
peptides that bound commercial anti-Aβ antibodies and AD plasma, while 
a small portion of the AD immunosignature was blocked with Aβ. 
 
 
Finally, I demonstrated that the antibody signature exhibited by 
elderly human subjects with or without AD remains mostly stable over 
time. Such antibody-binding pattern is different for each individual, in 
effect resembling a fingerprint, but sharing commonality with other 
individuals from the same group, an important effect when attempting to 
classify disease status. This particular property of the microarray platform, 
combined with its stability, suggests use as a diagnostic tool.  
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Without doubt, my studies have many limitations. Given the limited 
patient cohort, these results should be considered preliminary, but a proof 
of principle. I am currently assaying more plasma samples from AD 
patients and normal elderly controls to answer whether our microarray 
platform can be used to assist in the clinical classification of dementia. I 
also wish to confirm with larger numbers whether an immunosignature 
precedes the onset of cognitive impairment in humans. Given the slow 
progression of AD pathology (thought to develop many years in advance 
of symptom onset), an emerging humoral immune response, if any, could 
be detected and tracked in plasma.  
 
 
Closing remarks 
 
The patterns formed with antibody binding to microarrays may have 
potential as a diagnostic tool for many diseases, including AD. 
Understanding the stability of these signatures over time is important 
because if time-point variations are small, then larger sample pools could 
be used without concerns about noise dampening the signature out over 
time. Furthermore, if there is a personal component of the signature, it 
could be useful for monitoring disease progression or response to 
treatment. Relative to the first issue, AD signatures seem distinguishable 
from age-matched controls regardless of whether they were early or late 
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samples.  Relative to the second issue, there was clearly a personal 
component. The two samples from the same individual, including the PSP 
patient, were most similar to each other. This was also true for the non-AD 
samples, indicating that each person may have a distinctive 
immunosignature that is stable, analogous to a fingerprint.  
 
 
The ability to create a signature for AD could have value in several 
ways including confirmation of standard diagnosis, enrollment in clinical 
trials and monitoring responses to treatment.  Lacking practical tests to 
diagnose AD is not only problematic for patient care, it also represents a 
barrier for clinical trials, since many enrolled subjects will not have the 
disease of interest and therefore would not expect benefit from the studied 
intervention.  Antibody-based diagnostic tests have experienced renewed 
interest with the development of microarrays featuring plasma cytokines, 
random-sequence peptides or peptoids.  Surveying the antibody repertoire 
of individuals with or without a disease has many advantages. There are 
~109 estimated different antibody specificities, reflecting a history of 
exposure to a variety of antigens [10].  Antibodies are produced early in 
the course of diseases, amplify a signal, and are easily retrieved from 
body fluids, including blood.  Finally, antibodies are durable and can be 
easily stored, making them suitable for retrospective analysis.  Until 
recently, immunoassays were limited by the traditional view that the 
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eliciting antigen needs to be known and immobilized to detect an antibody 
response. However, we developed unbiased platforms to evaluate AD 
using random-sequence peptides, which principally behave as mimetics of 
unknown antigens.   
 
 
Ideally, AD should be detected at the pre-symptomatic or early 
symptomatic stages, when promising disease-modifying therapies are 
expected to exert greatest benefits.  Unfortunately, these stages are also 
ill-defined aspects of the disease, susceptible to diagnostic 
misclassification with current standards.  In summary, the evaluation of 
immunosignatures using random-sequence peptide arrays is a promising 
technique that can be applied to AD research. Future studies with more 
patients are needed to appraise the merits of immunosignaturing as a 
potential diagnostic test. 
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APPENDIX A  
EXPLORING THE PREDOMINANT FORM OF Aβ IN PLASMA  
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Using SDS-PAGE followed by western blotting of plasma samples 
from normal donors, I found that the predominant forms of circulating Aβ 
1-40 and Aβ 1-42 are oligomers, constituted mainly by dodeca- and 
hexamers (Figure 1). These oligomers can be detected with 4 different 
mono- and polyclonal antibodies raised against Aβ 1-40 and Aβ 1-42 and 
quantified using a densitometry software. The relevant bands are also 
recognized by a specific anti-oligomer antibody. The pattern of band 
immunoreactivity was replicated in 9 normal donors. I did not detect 
circulating monomers or dimers, even after separating plasma fractions 
using size-exclusion high performance liquid chromatography (HPLC).  
 
Figure 1: Circulating forms of Aβ. 
 
Fig. 1. Western blot of 3 plasma fractions separated using size-exclusion 
chromatography. There is a predominant 50 kDa band which roughly 
corresponds to the Aβ dodecamer. 
 
 
  106 
Based on this experiment, I postulate that individuals with AD (in 
particular, those with mutations leading to cerebral amyloidosis) may have 
circulating oligomers of different molecular weight compared to those in 
normal donors. Furthermore, AD cases may exhibit circulating monomers 
or dimers, while normal individuals do not. In other words, this very simple 
and widely available technology could be used as a diagnostic tool, if AD 
patients turn out to have a distinct pattern of immunoreactivity that sets 
them apart from normal individuals. 
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APPENDIX B 
TESTING ANTI-Aβ ANTIBODIES IN HUMAN PLASMA 
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To confirm whether Aβ antibodies are present in human plasma 
samples, I developed an Enzyme-linked immunosorbent assay (ELISA) in 
which polysterene plates were coated with Aβ (1-40 or 1-42), with a 
concentration of 10 uM in Sodium Carbonate / Bicar-bonate buffer 
(pH=11). Synthetic Aβ was purchased from AnaSpec Inc (San Jose, 
California). The plates were blocked with 5% Bovine Serum Albumin in 
PBS and 0.05% Tween 20 for 1 hour, followed by plasma from patients 
dissolved at 1:100 in PBS. The primary antibody was detected with anti-
human antibodies conjugated to HRP (Pierce) and then a colorimetric 
reaction was elicited by the addition of ABTS. Optic density was read at 
405 nm with a spectrophoto-meter. The tested plasma came from patients 
from the Brain-Bank at Sun Health Institute; Aβ levels were reported by Dr 
Alex Roher, who measured levels using a double-sandwich ELISA 
standardized in his laboratory.  
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Figure 2: Relationship between Aβ levels and anti-Aβ antibody titer 
 
 
Fig. 2. Aβ levels decreased as anti-Aβ antibody titers rose in non-demented 
elderly subjects (i.e., negative correlation between Aβ levels and anti-Aβ 
antibody titers; Parson‘s r= -0.475), whereas AD patients had a contrary trend 
(r=0.569). Although the number of samples is small (n=12 for each patient 
group), this illustrates the point that in spite of testing the same antigen, the Aβ-
binding antibodies may have different biological properties, depending on the 
selected population.
  
